US5674703A - Episomal vector systems and related methods - Google Patents
Episomal vector systems and related methods Download PDFInfo
- Publication number
- US5674703A US5674703A US08/161,286 US16128693A US5674703A US 5674703 A US5674703 A US 5674703A US 16128693 A US16128693 A US 16128693A US 5674703 A US5674703 A US 5674703A
- Authority
- US
- United States
- Prior art keywords
- replication
- papilloma virus
- episomal vector
- promoter
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013598 vector Substances 0.000 title claims abstract description 195
- 238000000034 method Methods 0.000 title claims abstract description 36
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 116
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 99
- 230000010076 replication Effects 0.000 claims abstract description 92
- 241001631646 Papillomaviridae Species 0.000 claims abstract description 83
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 83
- 101150029662 E1 gene Proteins 0.000 claims abstract description 49
- 101150082674 E2 gene Proteins 0.000 claims abstract description 45
- 230000004927 fusion Effects 0.000 claims abstract description 21
- 238000012423 maintenance Methods 0.000 claims abstract description 17
- 230000010502 episomal replication Effects 0.000 claims abstract description 15
- 230000014509 gene expression Effects 0.000 claims description 71
- 241000388186 Deltapapillomavirus 4 Species 0.000 claims description 41
- 210000001519 tissue Anatomy 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 230000003612 virological effect Effects 0.000 claims description 28
- 210000004185 liver Anatomy 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000003623 enhancer Substances 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 230000001131 transforming effect Effects 0.000 claims description 7
- 102000007469 Actins Human genes 0.000 claims description 6
- 108010085238 Actins Proteins 0.000 claims description 6
- 241000701806 Human papillomavirus Species 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims description 5
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims description 5
- 230000030833 cell death Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 230000003071 parasitic effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000011782 Keratins Human genes 0.000 claims description 4
- 108010076876 Keratins Proteins 0.000 claims description 4
- 108700020796 Oncogene Proteins 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 108010067390 Viral Proteins Proteins 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 4
- 239000003270 steroid hormone Substances 0.000 claims description 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 3
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 3
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- 102000004420 Creatine Kinase Human genes 0.000 claims description 3
- 108010042126 Creatine kinase Proteins 0.000 claims description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 3
- 102000003849 Cytochrome P450 Human genes 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims description 3
- 108010014258 Elastin Proteins 0.000 claims description 3
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims description 3
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 3
- 102100023162 L-serine dehydratase/L-threonine deaminase Human genes 0.000 claims description 3
- 102000047918 Myelin Basic Human genes 0.000 claims description 3
- 101710107068 Myelin basic protein Proteins 0.000 claims description 3
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims description 3
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims description 3
- 102000016349 Myosin Light Chains Human genes 0.000 claims description 3
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 3
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 3
- 102000043276 Oncogene Human genes 0.000 claims description 3
- 102000004067 Osteocalcin Human genes 0.000 claims description 3
- 108090000573 Osteocalcin Proteins 0.000 claims description 3
- 108010077077 Osteonectin Proteins 0.000 claims description 3
- 102000009890 Osteonectin Human genes 0.000 claims description 3
- 102000004264 Osteopontin Human genes 0.000 claims description 3
- 108010081689 Osteopontin Proteins 0.000 claims description 3
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 3
- 102000004338 Transferrin Human genes 0.000 claims description 3
- 108090000901 Transferrin Proteins 0.000 claims description 3
- 108010051583 Ventricular Myosins Proteins 0.000 claims description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 108060003196 globin Proteins 0.000 claims description 3
- 102000018146 globin Human genes 0.000 claims description 3
- 108020002326 glutamine synthetase Proteins 0.000 claims description 3
- 102000005396 glutamine synthetase Human genes 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 108020000318 saccharopine dehydrogenase Proteins 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- 102100022987 Angiogenin Human genes 0.000 claims description 2
- 102000007592 Apolipoproteins Human genes 0.000 claims description 2
- 108010071619 Apolipoproteins Proteins 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 241000701822 Bovine papillomavirus Species 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 102000004266 Collagen Type IV Human genes 0.000 claims description 2
- 108010042086 Collagen Type IV Proteins 0.000 claims description 2
- 102000004510 Collagen Type VII Human genes 0.000 claims description 2
- 108010017377 Collagen Type VII Proteins 0.000 claims description 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000007547 Laminin Human genes 0.000 claims description 2
- 108010085895 Laminin Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102100031784 Loricrin Human genes 0.000 claims description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 claims description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 claims description 2
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims description 2
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims description 2
- 108010089430 Phosphoproteins Proteins 0.000 claims description 2
- 102000007982 Phosphoproteins Human genes 0.000 claims description 2
- 108010076181 Proinsulin Proteins 0.000 claims description 2
- 108050002653 Retinoblastoma protein Proteins 0.000 claims description 2
- 101710172711 Structural protein Proteins 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 2
- 108010080146 androgen receptors Proteins 0.000 claims description 2
- 102000001307 androgen receptors Human genes 0.000 claims description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 2
- 108010072788 angiogenin Proteins 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 108010057085 cytokine receptors Proteins 0.000 claims description 2
- 102000003675 cytokine receptors Human genes 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 108091022911 insulin-like growth factor binding Proteins 0.000 claims description 2
- 102000028416 insulin-like growth factor binding Human genes 0.000 claims description 2
- 108010079309 loricrin Proteins 0.000 claims description 2
- 102000037983 regulatory factors Human genes 0.000 claims description 2
- 108091008025 regulatory factors Proteins 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108700042777 Bovine papillomavirus E1 Proteins 0.000 claims 1
- 108700023463 Bovine papillomavirus E2 Proteins 0.000 claims 1
- 101100239628 Danio rerio myca gene Proteins 0.000 claims 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 claims 1
- 101150039798 MYC gene Proteins 0.000 claims 1
- -1 PDGF Proteins 0.000 claims 1
- 101150001535 SRC gene Proteins 0.000 claims 1
- 101100174184 Serratia marcescens fosA gene Proteins 0.000 claims 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 101150078861 fos gene Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 102000016914 ras Proteins Human genes 0.000 claims 1
- 108010014186 ras Proteins Proteins 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 62
- 241001465754 Metazoa Species 0.000 abstract description 21
- 238000001415 gene therapy Methods 0.000 abstract description 12
- 210000004102 animal cell Anatomy 0.000 abstract description 10
- 241000282412 Homo Species 0.000 abstract description 7
- 210000005260 human cell Anatomy 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 75
- 108020004414 DNA Proteins 0.000 description 58
- 239000013612 plasmid Substances 0.000 description 26
- 239000002502 liposome Substances 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 210000003494 hepatocyte Anatomy 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 101710125507 Integrase/recombinase Proteins 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108010078791 Carrier Proteins Proteins 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102100027211 Albumin Human genes 0.000 description 6
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 108010002913 Asialoglycoproteins Proteins 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 3
- 102000007474 Multiprotein Complexes Human genes 0.000 description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108010084541 asialoorosomucoid Proteins 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 108020001096 dihydrofolate reductase Proteins 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 208000003154 papilloma Diseases 0.000 description 3
- 238000012753 partial hepatectomy Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 108010061952 Orosomucoid Proteins 0.000 description 2
- 102000012404 Orosomucoid Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 2
- 108010042606 Tyrosine transaminase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 230000027086 plasmid maintenance Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000178041 Ceropegia media Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000721550 Micromys minutus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006743 cytoplasmic accumulation Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 108700004049 glycosylated serum Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20041—Use of virus, viral particle or viral elements as a vector
- C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Definitions
- the present invention relates generally to episomal vector systems for gene therapy and methods of attaining episomal vector replication in human and other animal cells.
- the episomal vector systems contain papilloma virus nucleic acid sequences.
- the papillomaviruses are widely found in nature and have been recognized primarily in higher vertebrates. They have been characterized from cattle, rabbits, horses, dogs, sheep, elk, deer, nonhuman primates, the harvest mouse, the multimammate mouse and humans. Over 50 distinct human papilloma viruses (“HPV”) have been described. Genomic sequences of several of these, including HPV-1, HPV-11, HPV-16 and HPV-18 have been determined.
- the papillomaviruses are highly species specific and have a specific tropism for squamous cells. Viral replication is restricted to the most terminally differentiated keratinocytes of the epithelium, although viral DNA can be found within basal and parabasal cells of a papilloma. Viral transcripts have been found in the basal cells of the epidermis, but late gene expression occurs only in the terminally differentiated cells. Thus, viral replication is latent in basal cells and productive in the more terminally differentiated cells within the upper layers of the epithelium.
- Papillomaviruses encode trans-acting factors that modulate viral transcription.
- the first of these factors to be described was the E2 protein.
- the E2 Open Reading Frame (“ORF") contains domains that are relatively well-conserved among the papillomaviruses.
- E2 proteins are DNA-binding proteins which consist of two highly conserved domains joined by a more degenerate central region which is considered to be a linker region. Limited homology of E2 protein with the cellular oncogene c-mos has been noted.
- BPV-1 Bovine papilloma virus type 1
- BPV-1 Bovine papilloma virus type 1
- the BPV-1 genome is a double stranded, closed circle of 7,945 base pairs. The entire sequence is known.
- the virus infects both dermal fibroblasts and epidermal epithelial cells but viral particles are produced only in terminally differentiated epidermal keratinocytes.
- the cloned viral DNA can transform mouse C127I fibroblasts in culture in which the viral DNA is maintained as a multicopy extrachromosomal nuclear plasmid with a stable copy number of 50-100 copies per cell.
- a 5.4 kb subgenomic fragment of the viral genome (referred to as the ⁇ 69% region ⁇ ) is sufficient for transformation of C127I cells in vitro and contains all eight of the viral open reading frames. At the 5' end of the 69% fragment there is a 1 kb stretch devoid of open reading frames referred to as the upstream regulatory region. This region contains several promoters/enhancers and the viral origin of replication. In cells transformed by the virus, only a few of the viral open reading frames are expressed. The viral origin of replication has been mapped and sequenced.
- the human papilloma viruses contain genes and replication control sequences similar to those found in BPV-1 and other papilloma viruses.
- the present invention provides papilloma virus episomal vector systems and methods for papilloma virus episomal vector replication in a variety of human and animal cells not normally permissive for replication of a particular papilloma virus or for maintenance of a particular papilloma virus sequence.
- episomal vector systems containing papilloma virus E1 and E2 genes and a papilloma virus origin of replication. These vectors are capable of episomal replication and due to their small size allow for insertion of a therapeutic nucleic acid sequence, which may be efficiently expressed in a human or other animal cell.
- the invention features an episomal vector system for gene therapy in humans or animals which contains a polyfunctional nucleic acid sequence from a papilloma virus, the polyfunctional nucleic acid sequence including an origin of replication, a vector maintenance sequence, a first promoter and a unique restriction site for insertion of one or more therapeutic nucleic acid sequences; a first expression cassette containing a papilloma E1 gene sequence and a second promoter to drive transcription of the E1 gene; a second expression cassette containing a papilloma E2 gene sequence and a third promoter to drive transcription of the E2 gene; the first and second expression cassettes cloned into an episomal vector; and the episomal vector system includes one or more episomal vectors, each capable of episomal replication in a human or other animal cell.
- this invention features an episomal vector system for gene therapy in humans or animals which contains a polyfunctional nucleic acid sequence from BPV-1 (nucleotides 4780 to 471 from the BPV-1 genome, (e.g., 3636 bp in length)) in a vector, SEQ. ID. NO. 1, the polyfunctional nucleic acid sequence including an origin of replication, a vector maintenance sequence, a first promoter and a unique restriction site for insertion of one or more therapeutic nucleic acid sequences; a first expression cassette containing a BPV-1 E1 gene sequence, SEQ. ID. NO. 2, and a second promoter to drive transcription of the E1 gene; a second expression cassette containing the BPV-1 E2 gene sequence, SEQ.
- the episomal vector system includes one or more episomal vectors each, capable of episomal replication in a human or animal cell.
- this invention features an episomal vector system for gene therapy in humans or animals which contains a polyfunctional nucleic acid sequence from a Human papilloma virus ("HPV") in a vector, the polyfunctional nucleic acid sequence including an origin of replication, a vector maintenance sequence, a first promoter and a unique restriction site for insertion of one or more therapeutic nucleic acid sequences; a first expression cassette containing a HPV E1 gene sequence and a second promoter to drive transcription of the E1 gene; a second expression cassette containing a HPV E2 gene sequence and a third promoter to drive transcription of the E2 gene; the first and second expression cassettes cloned into a vector; and the episomal vector system includes one or more episomal vectors each, capable of episomal replication in a human or animal cell.
- HPV Human papilloma virus
- vector refers to nucleic acid derived from a plasmid, cosmid, phagemid or bacteriophage, into which fragments of nucleic acid may be inserted or cloned.
- the vector can contain one or more unique restriction sites for this purpose, and may be capable of autonomous replication in a defined host or organism such that the cloned sequence is reproduced.
- the vector molecule can confer some well-defined phenotype on the host organism which is either selectable or readily detected.
- Some components of a vector may be a DNA molecule further incorporating a DNA sequence encoding regulatory elements for transcription, translation, RNA stability and replication.
- the term "origin of replication” refers to a papilloma virus DNA sequence at which nucleic acid, typically DNA, synthesis is initiated.
- the minimal sequence for the BPV-1 origin of replication is defined by a 41 nucleotide sequence containing bases 7935 to 30. Those of ordinary skill in the art can determine other minimum sequences in other papilloma viruses using routine procedures.
- vector maintenance sequence refers to a cis-acting nucleic acid sequence contained in a vector and which confers long term stable vector replication to the vector.
- a vector containing a vector (plasmid) maintenance sequence will remain unrearragned and stably maintained at a constant copy number. See Lusky, M. et al., Characterization of the Bovine Papilloma Virus Plasmid Maintenance Sequences. Cell 36(2) 391-401 (1984).
- therapeutic nucleic acid sequence refers to a genetic material of interest which expresses a protein, polypeptide or RNA when incorporated into the cell of an animal or human.
- a therapeutic nucleic acid sequence is positionally and sequentially oriented within the episomal vector with other necessary elements such that the therapeutic nucleic acid sequence or sequences can be transcribed and when necessary translated into the cells in which the episomal vector has been incorporated.
- Other elements can include promoters, introns, untranslated regions, non-coding regions, regulatory regions, etc.
- One skilled in the art will be able to determine the specific necessary elements for each specific sequence and application.
- the genetic material which is incorporated into the therapeutic nucleic acid sequence or sequences can be any DNA or RNA.
- the nucleic acid can be: (1) not normally found in the tissues of the cell; (2) normally found in a specific tissue but not expressed at physiologically significant levels; (3) normally found in specific tissue and normally expressed at physiological levels in the specific tissue; (4) any other DNA or RNA which can be modified for expression in a specific tissue and (5) any combination of the above.
- therapeutic nucleic acid sequences selected from the group consisting of nucleic acid sequences encoding receptors, enzymes, ligands, regulatory factors, and structural proteins.
- Therapeutic nucleic acid sequences selected from the group consisting of nucleic acid sequences encoding nuclear proteins, cytoplasmic proteins mitochondrial proteins, secreted proteins, plasmalemma-associated proteins, serum proteins, viral antigens, bacterial antigens, protozoal antigens and parasitic antigens.
- Therapeutic nucleic acid sequences selected from the group consisting of nucleic acid sequences encoding proteins, lipoproteins, glycoproteins, phosphoproteins and nucleic acid.
- Proteins or polypeptides which can be expressed using the episomal vector of the present invention include hormones, growth factors, enzymes, clotting factors, apolipoproteins, receptors, drugs, oncogenes, tumor antigens, tumor suppressors, viral antigens, parasitic antigens and bacterial antigens.
- these compounds include proinsulin, insulin, growth hormone, androgen receptors, insulin-like growth factor I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor TGF- ⁇ , TGF- ⁇ , PDGF, angiogenesis factors (acidic fibroblast growth factor, basic fibroblast growth factor and angiogenin), matrix proteins (Type IV collagen, Type VII collagen, laminin), phenylalaninehydroxylase, tyrosinehydroxylase, oncogenes (ras, fos, myc, erb, src, sis, jun), E6 or E7 transforming sequence, p53 protein, Rb gene product, cytokine receptor, IL-1, IL-6, IL-8, viral capsid protein, and proteins from viral, bacterial and parasitic organisms which can be used to induce an immunologic response, and other proteins of useful significance in the body.
- angiogenesis factors acidic fibroblast growth factor, basic fibroblast growth factor and angiogenin
- matrix proteins Type IV
- the compounds which can be incorporated are only limited by the availability of the nucleic acid sequence for the protein or polypeptide to be incorporated.
- One skilled in the art will readily recognize that as more proteins and polypeptides become identified they can be integrated into the episomal vector and expressed in the animal or human tissue.
- expression cassette refers to a nucleic acid sequence which is capable of being transcribed and translated to result in production of a polypeptide.
- E1 gene sequence means a gene which encodes the E1 polypeptide which is the protein product of the E1 open reading frame of a papillomavirus.
- the E1 protein possesses the ability to bind to homologous or heterologous a cis-acting DNA sequence, e.g., a papillomavirus origin of replication region, thereby targeting this region for the initiation of DNA synthesis by cellular DNA-synthesis proteins.
- E2 gene, sequence means a gene which encodes the E2 polypeptide which is the protein product of the E2 open reading frame of a papillomavirus.
- the E2 protein possesses the ability to trans-activate, in the presence of the papillomavirus E1 protein, the replication of homologous or heterologous DNA containing a cis-acting DNA sequence, e.g., a papillomavirus origin of replication region, by cellular DNA-synthesis proteins.
- any such nucleic acid sequence which encodes a portion of an E1 or E2 protein which exhibits the functional characteristics of an E1 or E2 protein as defined above are within the preferred embodiment.
- These protein sequences comprising less than a whole E1 or E2 protein but which are nevertheless functional, may be mapped by mutational analysis or various clones may be created and the activity of proteins expressed from such clones assayed or other routine testing as is known in the art may be utilized.
- first and/or second and/or third promoter may be asteroid regulated promoter, regulatable by asteroid hormone receptor gene switch as set forth in United States patent application entitled "Mutated Steroid Hormone Receptors, Methods for their Use and Molecular Switch for Gene Therapy” filed Sep. 2, 1993, Ser. No. 07/939,246, incorporated herein by reference.
- asteroid hormone receptor gene switch By including these steroid regulatable elements, the administration of a steroid hormone analog will induce episomal replication. Cessation of administration of the steroid hormone will result in the cessation of episomal vector replication.
- the episomal vector systems of this invention have a discrete half-life.
- administered-compound-regulatable promoter is meant a promoter which is activated in response to a exogenously administered substance, where the administered substance is not typically present in a human or other animal.
- an episomal vector containing a thymidine kinase gene may be administered.
- a substrate for thymidine kinase as is known in the art, a toxic, phosphorylated nucleic acid base is generated which results in cell death, effectively causing the cessation of production of any other gene product contained in an administered episomal vector.
- the first, second or third promoters can be identical or can be different when the promoter is from a ubiquitously expressed gene.
- ubiquitously expressing promoters include phosphoglycerolkinase, Rous Sarcoma Virus Long Terminal Repeat (“RSV-LTR”), Immediate Early Cytomegalovirus (“IE-CMV”) or dihydrofolate reductase (“DHFR”) promoters.
- the first, second and third promoters can be identical or can be different when the promoter is from a gene expressed in a tissue-specific manner.
- tissue-specific promoters are different, they must all be capable of providing expression in a specific tissue type.
- three different liver specific promoters may be utilized.
- tissue-specific promoters include creatine kinase promoter, insulin promoter, immunoglobulin heavy chain promoter/enhancer, albumin enhancer/promoter, tyrosine aminotransferase promoter, transferrin promoter, cytochrome P-450 promoter, apolipoprotein E promoter, apolipoprotein A-1 promoter and ⁇ -actin promoter for liver expression, elastin, alpha-1 (I) collagen, keratin K1, K6 and loricrin for skin expression; alpha actin, beta myosin heavy chain, myosin light chain, aldolase A for muscle expression; type 4 collagenase, Clara protein, serine dehydratase for lung expression; myelin basic protein, beta amyloid precursor protein, glutamine synthetase, tyrosine hydroxylase for brain expression; globin, Immunoglobulin heavy and light chains for blood cell expression; and osteonectin, osteocalcin, osteopontin
- tissue-specific promoter means that the promoter will allow transcription of RNA from the vector primarily only in a specific tissue in which the promoter is activated. For example, muscle cell specific promoters will only allow transcription in muscle cells. However, even with tissue-specific promoters some low level (about 10% or less than that observed in the desired tissue) expression might occur in other cell types. The promoter would still be defined as tissue-specific. Methods of achieving tissue-specific gene expression as set forth in International Publication No. WO 93/09236, filed Nov. 3, 1992 and published May 13, 1993; International Application No. PCT/US93/03993, filed Apr. 28, 1993; International Application No. PCT/US93/03985, filed Apr. 28, 1993; and U.S. patent application entitled “Specific Expression Vectors and Methods of Use", filed Nov. 1, 1993 and U.S. patent application entitled “Keratin K1 Expression Vectors and Methods of Use”; all (including drawings) are hereby incorporated by reference herein.
- albumin enhancer/promoter IE-CMV, RSV-LTR or DHFR promoters are used.
- the E1 and E2 or E1/E2 gene fusion sequences are a distance of at least about 1 Kb 5' and 3' from the origin of replication.
- the origin of replication may be selected from one type of papilloma virus, for example BPV-1
- the E1 gene sequence may be selected from the same papilloma virus or another papilloma virus, for example HPV
- the E2 gene sequence may be selected from the same type of papilloma virus as used for the origin of replication or for the E1 gene sequence or a different papilloma virus than one or both of the papilloma viruses from which the origin of replication and E1 gene sequence were selected from.
- Combinations of, or parts thereof, such as the origin of replication, E1 gene sequence and E2 gene sequence or E1/E2 gene fusion sequence, as set forth above, may be combined in a vector and assayed as is known in the art to determine functional combinations thereof.
- E1/E2 fusion gene Another embodiment of the present invention includes the use of an E1/E2 fusion gene.
- EMC encephalomyocarditis
- polio virus in the production of polycistronic messages.
- both proteins would be encoded on a single mRNA species to insure production of both In this embodiment, only one ribonucleic acid species, translation of which will result in the production of two separate proteins, would be necessary to support maintenance of episomal replication.
- the fusion gene will contain at least the trans-activation region of the E2 protein.
- a papilloma virus origin of replication and a first promoter transcriptionally linked to a therapeutic nucleic acid sequence are contained on a first episomal vector and a papilloma virus origin of replication, a second promoter transcriptionally linked to a papilloma virus E1 gene sequence and a third promoter transcriptionally linked to a papilloma virus E2 gene sequence are contained on a second episomal vector.
- a papilloma virus origin of replication a first promoter transcriptionally linked to a therapeutic nucleic acid sequence and either one of a second promoter transcriptionally linked to a papilloma virus E1 gene sequence or a third promoter transcriptionally linked to a papilloma virus E2 gene sequence are contained on a first episomal vector and a papilloma virus origin of replication, and the other one of a second promoter transcriptionally linked to a papilloma virus E1 gene sequence and a third promoter transcriptionally linked to a papilloma virus E2 gene sequence are contained on a second episomal vector.
- a three vector system may be utilized, each vector containing a papilloma virus origin of replication, and one episomal vector containing a first promoter transcriptionally linked to a therapeutic nucleic acid sequence.
- a papilloma virus origin of replication and a first promoter transcriptionally linked to a therapeutic nucleic acid sequence are contained on a first episomal vector and a second promoter transcriptionally linked to an E1/E2 fusion gene sequence, the fusion gene sequence containing at least the transactivation region of the E2 gene sequence, are contained on a second episomal vector.
- the separate vectors are co-administered such that all species of vector are present in at least some of the same cells.
- a method of stably transforming a cell in a human or other animal cell which is accomplished by introducing the episomal vector into the cell. Once introduced into the cell, a stably transformed cell is made.
- stable transformation refers to episomal transformation in which the introduced therapeutic nucleic acid sequence or sequences is not incorporated into the chromosomes of the whole cell, but rather is replicated as an extra-chromosomal element. This leads to a stable change or transformation of a given characteristic of a cell.
- transformed refers to a process for making or introducing a stable change in the characteristics (express phenotype) of a cell by the mechanism of gene transfer whereby DNA or RNA is introduced into a cell in a form where it expresses a specific gene product or alters an expression of or affects endogenous gene products.
- this process involves the introduction of the episomal vector into the cell.
- the episomal vector can be introduced into the cell by a variety of methods including microinjection, CaPO 4 precipitation, lipofection (liposome fusion), use of a gene gun and DNA vector transporter.
- DNA vector transporter refers to those molecules which bind to the episomal vector system of the present invention and are capable of being taken up by cells.
- a DNA transporter is a molecular complex capable of non-covalent binding to the DNA of the episomal vector system and efficiently transporting the DNA through the cell membrane. Although not necessary, it is preferable that the transporter also transport the DNA through the nuclear membrane.
- an episomal vector system for gene therapy treatment of uncontrolled cellular proliferative diseases, such as cancer.
- An episomal vector containing a nucleic acid sequence encoding a polypeptide which when expressed results in cell death is administered to a human or other animal.
- FIG. 1 shows a schematic representation of a BPV-1 episomal vector.
- the viral origin of replication (ORIGIN) and Vector Maintenance Sequence (VMS) locations are indicated within the BPV-1 polyfunctional nucleic acid sequence (nucleotides 4780 to 471 from the BPV-1 genome, 3636 bp).
- the Mlu I site is unique and is used to insert a therapeutic nucleic acid sequences or sequences. Insertions at this site do not interfere with viral replication.
- FIG. 2 shows replication of BPV-1 origin-containing plasmids in Hepa1A cells.
- FIG. 3 shows replication of BPV-1 origin plasmid only in the presence of both E1 and E2.
- FIG. 4 shows a BPV-1 genomic map.
- a variety of eukaryotic expression vectors have been constructed from the BPV-1 genome utilizing the 69% region to drive episomal replication in C127I cells. These vectors have been used to study inducible elements as well as to synthesize a variety of compounds. All of these studies have been carried out in C127I or ID-13 cells (derived from C127I cells which contain multiple integrated copies of the BPV-1 genome and produce viral proteins.) It is known that the viral E1 and E2 proteins are necessary in conjunction with the origin of replication to support episomal replication of plasmids containing the origin.
- the plasmids containing an endogenous vital promoter to drive transcription of the viral open reading frames encoded in E1 and E2 and a viral origin do not replicate.
- the immediate early cytomegalovirus (IECMV) promoter was used to drive the expression of E1 and E2
- episomal replication was observed.
- the cell types used are all epithelial or fibroblast-like and these are the cell types normally permissive for BPV-1 replication. It would be useful to have a vector for gene therapy which would replicate in a broad range of cell types and allow for expression of a therapeutic nucleic acid sequence or sequences contained in the vector.
- Non-viral methods of delivery such as receptor-mediated DNA delivery have been used to introduce DNA to the liver in vivo. Only transient expression has been observed from constructs targeted to the liver without prior partial hepatectomy. If a partial hepatectomy proceeds the introduction of the DNA/protein conjugate, the period of expression is extended, but not indefinitely.
- the ability to achieve long-term expression of targeted DNAs in which the risks and costs of invasive surgical procedure such as partial hepatectomy are avoided is of great importance.
- the present invention utilizing an episomally replicating vector containing portions of a papilloma virus genome provides a solution to this problem.
- Particular regions of the BPV-1 genome can be stimulated in the quiescent liver or other tissues and can be stably maintained long-term when targeted to the liver or other organs by receptor-mediated DNA delivery.
- One embodiment of the present invention includes an episomal vector system for gene therapy in humans or animals comprising a polyfunctional nucleic acid sequence of BPV-1 in a vector, the polyfunctional nucleic acid sequence including an origin of replication, a vector maintenance sequence a first promoter and a unique restriction site; for example, a unique Mlu I or other restriction enzyme site as are known in the art, for insertion of one or more therapeutic nucleic acid sequences; a first expression cassette containing the BPV-1 E1 gene sequence and a second promoter to drive transcription of the E1 genes; a second expression cassette containing the BPV-1 E2 gene sequence and a third promoter to drive transcription of the E2 gene; the first and second expression cassettes cloned into the vector and the episomal vector system includes one or more episomal vectors each, capable of episomal replication in a human or animal cell.
- FIG. 1 there is shown a schematic representation of the BPV-1 episomal vector using a pUC 19 plasmid.
- the "BPV-1 origin" region is approximately 1457 base pairs in length and includes a nucleotide sequence from 6959 to 7945/1 and 7945/1 to 470 of the BPV-1 genome.
- the origin of replication and plasmid maintenance sequence locations are indicated within the BPV-1 polyfunctional nucleic acid sequence.
- the origin of replication corresponds to nucleotide 7945/1 of the BPV-1 genome.
- the minimal sequence for the BPV-1 origin of replication is defined by a 41 nucleotide sequence containing bases 7935 to 30.
- a unique Mlu I site is used to insert a therapeutic nucleic acid sequence or sequences. Insertions at this site do not interfere with viral replication.
- FIG. 1 there is also shown the E1 gene sequence and an E2 gene sequence with their promoters. The promoters can be identical or different. The location of the E1 and E2 gene sequences to the origin of replication is not important; except that they must be at least about 1 kb 5' and 3' from the origin of replication, otherwise they will interfere with replication of the episomal vector.
- the episomal vector mimics the arrangements of the E1 and E2 gene sequences relative to the replication origin found in the viral genome.
- the insertion of strong heterologous promoters in close proximity to the BPV-1 origin of replication interferes with replication. For this reason, promoters driving the expression of the E1 and E2 gene sequences are placed away from the viral origin to minimize this "squelching effect.”
- the E1 and E2 gene sequences are oriented in a head-to-tail arrangement of the basic layout of the episomal vector as depicted in FIG. 1.
- the vector is constructed to allow for the insertion of different promoter elements upstream of the E1 and E2 gene sequences.
- Unique cloning sites are also present at various sites in the construct to allow for the insertion of reporter and or therapeutic nucleic acid sequences.
- first, second and third promoters can be identical or different. They can be from ubiquitously expressed genes or from tissue-specific expressed genes. However, where the tissue-specific promoters are different, they must all be capable of providing expression in a specific tissue type. For example, three different liver specific promoters may be utilized. Examples of some promoters which have been found useful in the present invention include the promoter for ubiquitously expressed genes including phosphoglycerolkinase, IE-CMV, RSV-LTR or DHFR.
- Tissue-specific promoters include insulin promoter for pancreatic expression, creatine kinase promoter for skeletal muscle expression, immunoglobulin heavy chain promoter/enhancer for B-cell expression, albumin enhancer/promoter, tyrosine aminotransferase promoter, transferrin promoter, cytochrome P-450 promoter, apolipoprotein E promoter, apolipoprotein A-1 promoter and ⁇ -actin promoter for liver expression, elastin, alpha-1 (I) collagen, keratin for skin expression; alpha actin, beta myosin heavy chain, myosin light chain, aldolase A for muscle expression; type 4 collagenase, Clara protein, serine dehydratase for lung expression; myelin basic protein, beta amyloid precursor protein, glutamine synthetase, tyrosine hydroxylase for brain expression; globin, Immunoglobulin heavy and light chains for blood cell expression; and osteonectin, osteocalcin
- EMC encephalomyocarditis
- the most important criteria used in the selection of a promoter to drive the expression of the E1 and E2 viral replication factors and the reporter gene nucleic acid sequences or therapeutic nucleic acid sequence or sequences is the ability of that promoter to drive long-term expression in the tissue of choice. Tissue specificity can be achieved at the level of delivery and promoters will not be eliminated as potential candidates should they be expressed in tissues other than the specific tissue of interest. Each therapy will have its own set of constraints with respect to the specificity of expression required and the level necessary for the treatment to have efficacy. In the preferred vectors, the primary objective is to achieve the highest sustained level of expression possible. Modulation of expression is undertaken when specific therapy requirements become apparent.
- the long terminal repeat of the Rous Sarcoma Virus (RSV-LTR) is used in the preferred embodiment.
- the RSV-LTR promoter is capable of driving high levels of expression both in cultured episomal cells and in primary hepatocytes and a variety of other tissues. High level expression is seen in hepatocytes transduced both in vivo and in vitro.
- the LTR of Moloney Murine leukemic virus has also been used to drive expression in vivo.
- the albumin enhancer/promoter has been the preferred embodiment for liver cells.
- the albumin enhancer/promoter is a strong promoter relative to other promoters expressed in the liver. This promoter has been found to drive long-term expression in both primary hepatocytes and retrovirally transduced implanted hepatocytes.
- An additional advantage of this promoter is the tissue specificity of the albumin regulatory regions. Any leakiness in the delivery system will be less likely to drive transcription in any tissues other than the liver.
- the E1 and E2 gene sequences and the therapeutic nucleic acid sequence or sequences, origin of replication and vector maintenance sequences are all contained in a single vector.
- the arrangement of these elements for optimum replication and maintenance will depend on the type of tissue being transformed, as well as the specific therapeutic nucleic acid sequence or sequences being used.
- the Hepa1A replication assay system described in Example 2 can be used to optimize the vectors for these criteria.
- the episomal vector containing a particular therapeutic nucleic acid sequence or sequences can be administered prophylactically, or to patients having a disease or condition treatable by supplying and expressing a particular therapeutic nucleic acid sequence or sequences, e.g., by exogenous delivery of a naked episomal vector containing a therapeutic nucleic acid sequence or sequences, an episomal vector containing a therapeutic nucleic acid sequence associated with specific carriers, by means of an appropriate delivery vehicle, e.g., a liposome, by use of iontophoresis, electroporation and other pharmacologically approved methods of delivery.
- Routes of administration may include intramuscular, intravenous, aerosol, oral (tablet or pill form), topical, systemic, ocular, as a suppository, intraperitoneal and/or intrathecal.
- an episomal vector containing a therapeutic nucleic acid sequence or sequences will depend on the use of the episomal vector.
- Some methods of delivery that may be used include:
- At least three types of delivery strategies are useful in the present invention, including: Injection of naked episomal vector containing a therapeutic nucleic acid sequence or sequences, or injection of charge modified episomal vector containing a therapeutic nucleic acid sequence or sequences, or particle carrier drug delivery vehicles.
- Unmodified nucleic acid sequence encoding episomal vector containing a therapeutic nucleic acid sequence or sequences like most small molecules, are taken up by cells, albeit slowly.
- the episomal vector containing a therapeutic nucleic acid sequence or sequences may be modified in ways which reduce its charge but will maintain the expression of specific functional groups in the final translation product. This results in a molecule which is able to diffuse across the cell membrane, thus removing the permeability barrier.
- Intravenous administration with a drug carrier designed to increase the circulation half-life of the nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences can be used.
- the size and composition of the drug carrier restricts rapid clearance from the blood stream.
- the carrier made to accumulate at the desired site of transfer, can protect the nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences from degradative processes.
- Drug delivery vehicles are effective for both systemic and topical administration. They can be designed to serve as a slow release reservoir, or to deliver their contents directly to the target cell.
- An advantage of using direct delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles have been shown to increase the circulation half-life of drugs which would otherwise be rapidly cleared from the blood stream.
- Some examples of such specialized drug delivery vehicles which fall into this category are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.
- liposomes are preferred. Liposomes increase intracellular stability, increase uptake efficiency and improve biological activity.
- Liposomes are hollow spherical vesicles composed of lipids arranged in a similar fashion as those lipids which make up the cell membrane. They have an internal aqueous space for entrapping water soluble compounds and range in size from 0.05 to several microns in diameter. Several studies have shown that liposomes can deliver nucleic acids to cells and that the nucleic acid remains biologically active.
- Lipofectin a liposome delivery vehicle originally designed as a research tool, Lipofectin, has been shown to deliver intact mRNA molecules to cells yielding production of the corresponding protein.
- Liposomes offer several advantages: They are non-toxic and biodegradable in composition; they display long circulation half-lives; and recognition molecules can be readily attached to their surface for targeting to tissues. Finally, cost effective manufacture of liposome-based pharmaceuticals, either in a liquid suspension or lyophilized product, has demonstrated the viability of this technology as an acceptable drug delivery system.
- controlled release drug delivery systems such as nanoparticles and hydrogels may be potential delivery vehicles for a nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences.
- These carriers have been developed for chemotherapeutic agents and protein-based pharmaceuticals, and consequently, can be adapted for nucleic acid delivery.
- nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences to neutralize negative charge may be all that is required for penetration.
- the nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence receptor can be co-formulated with permeability enhancers, such as Azone or oleic acid, in a liposome.
- the liposomes can either represent a slow release presentation vehicle in which the modified nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences and permeability enhancer transfer from the liposome into the targeted cell, or the liposome phospholipids can participate directly with the modified nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences and permeability enhancer can participate directly thereby facilitating cellular delivery.
- both the nucleic acid encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences and permeability enhancer can be formulated into a suppository formulation for slow release.
- the nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences may also be systemically administered.
- Systemic absorption refers to the accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include: intravenous, intramuscular, subcutaneous, intraperitoneal, intranasal, intrathecal and ophthalmic.
- a gene gun may also be utilized. Administration of DNA-coated microprojectiles by a gene gun requires instrumentation but is as simple as direct injection of DNA. A construct bearing the gene of interest is precipitated onto the surface of microscopic metal beads. The microprojectiles are accelerated with a shock wave or expanding helium gas, and penetrate tissues to a depth of several cell layers.
- This approach permits the delivery of foreign genes to the skin of anesthetized animals.
- This method of administration achieves expression of transgenes at high levels for several days and at detectable levels for several weeks.
- Each of these administration routes exposes the nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences to an accessible targeted tissue.
- Subcutaneous administration drains into a localized lymph node which proceeds through the lymphatic network into the circulation. The rate of entry into the circulation has been shown to be a function of molecular weight or size.
- the use of a liposome or other drug carrier localizes the nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence at the lymph node.
- the nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences can be modified to diffuse into the cell, or the liposome can directly participate in the delivery of either the unmodified or modified nucleic acid sequence encoding an episomal vector containing a therapeutic nucleic acid sequence or sequences to the cell, Liposomes injected intravenously show accumulation in the liver, lung and spleen. The composition and size can be adjusted so that this accumulation represents 30% to 40% of the injected dose. The remaining dose circulates in the blood stream for up to 24 hours.
- the chosen method of delivery should result in cytoplasmic accumulation and molecules should have some nuclease-resistance for optimal dosing. Nuclear delivery may also be used. Most preferred delivery methods include liposomes (10-400 nm), hydrogels, controlled-release polymers, microinjection or electroporation (for ex vivo treatments) and other pharmaceutically applicable vehicles.
- the dosage will depend upon the disease indication and the route of administration but should be between 1-1000 ⁇ g/kg of body weight/day.
- the duration of treatment will extend through the course of the disease symptoms, possibly continuously.
- the number of doses will depend upon disease delivery vehicle and efficacy data from clinical trials.
- the DNA transporter system comprises a plurality of a first DNA binding complex, the complex including a first binding molecule capable of non-covalently binding to DNA, the first binding molecule covalently linked to a surface ligand, the surface ligand capable of binding to a cell surface receptor; a plurality of a second DNA binding complex, the complex including a second binding molecule capable of non-covalently binding to DNA, the second binding molecule covalently linked to a nuclear ligand, the nuclear ligand capable of recognizing and transporting a transporter system through a nuclear membrane; wherein the plurality of first and second DNA binding complexes are capable of simultaneously, non-covalently binding to a specific DNA.
- a plurality of a third DNA binding complex may be used, the complex includes a third binding molecule capable of non-covalently binding to DNA, the third binding molecule covalently linked to a virus; wherein the plurality of third DNA binding complexes are capable of simultaneously, non-covalently binding to a specific DNA.
- the first binding molecule, the second binding molecule and third binding molecule can each be selected from the group consisting of spermine, spermine derivative, histones, cationic peptides and polylysine.
- Spermine derivative refers to analogues and derivatives of spermine and include compounds as set forth in International Publication No. WO 93/18759, filed Mar. 19, 1993 and published Sep. 30, 1993, hereby incorporated by reference.
- An episomal vector containing a therapeutic nucleic acid sequence or sequences may be administered utilizing an ex vivo approach whereby cells are removed from an animal, transduced with the episomal vector containing a therapeutic nucleic acid sequence or sequences and reimplanted into the animal.
- the liver can be accessed by an ex vivo approach by removing hepatocytes from an animal, transducing the hepatocytes in vitro with the episomal vector containing a therapeutic nucleic acid sequence or sequences and reimplanting them into the animal (e.g., as described for rabbits by Chowdhury et al., Science 254:1802-1805, 1991, or in humans by Wilson, Hum. Gene Ther. 3:179-222, 1992) incorporated herein by reference.
- the episomal vector containing a therapeutic nucleic acid sequence or sequences may be administered utilizing an in vivo approach whereby the gene will be administered directly to an animal by intravenous injection, intramuscular injection, or by catheterization and direct delivery of the gene via the blood vessels supplying the target organ.
- the parent plasmid for this construction is pUCPst which consists of pUC18 containing the BPV-1 sequence between bases 4780 and 471 bp (3636 bp).
- the origin of replication in this plasmid is located at base 7945/1.
- the unique sites in the multiple cloning region of pUCPst are used for the insertion of gene sequences for E1 and E2.
- IECMV promoter driven cassettes for E1 and E2 are obtained with EcoRI (5') to XhoI (3') digests of pCGEAG and pCGE2. The ends of these fragments are filled in with the Klenow fragment of DNA polymerase and linkers are added.
- the gene sequences are then cloned into the Hind III (E2) and Bam HI sites (E1), in a head to tail configuration as depicted in FIG. 1.
- the method of Ustav and Stenlund, "Transient Replication of BPV-1 Requires Two Viral Polypeptides Encoded by the E1 and E2 Open Reading Frames" EMBO J. 10:449-457 (1991) is used for the replication assay in episomal cells.
- the origin plasmid designated pUC/Alu contains the viral sequences between 7890 and 52 (107 bp) in pUC19.
- the plasmid pUC/Pst contains a viral sequence between 4780 and 471 (3636 bp).
- the expression vectors for E1 and E2 are driven by the IECMV promoter.
- the cells (10 7 ) are mixed with a total of 40 ⁇ g of DNA and 500 ⁇ l of serum-containing media.
- Electroporation is then carried out in the Gene-Pulsar apparatus (Bio-Rad) with a 230-Volt, 960 ⁇ Fd pulse.
- Cells are pelleted through 10 ml of serum-containing media and plated on 6 ⁇ 10 cm dishes.
- Extrachromosomal DNA is prepared at 24-hour time points and half of the recovered DNA was digested with BamHI and DpnI, electrophoresed on 0.8%, 1X TAE gels and Southern blotted. Filters were hybridized with pUC19 sequences generated by radioactive labelling with random primers.
- the results obtained from mouse hepatoma cell lines HepaIA are shown in FIG. 2. Time points in each set are 24, 48, 72, 96, and 120 hours.
- Newly replicated material in mammalian cells was resistant to digestion by DpnI while residual bacterial plasmid DNAs were sensitive.
- the DpnI resistant material (replicated DNA) is linearized by BamHI and forms a 2793 bp band for replicated pUC/Alu (see Control Lane 1 and Lane 7-11), and a 6322 bp band for replicated pUC/Pst (see Control Lane 2 and Lanes 14-18).
- the DpnI sensitive material unreplicated DNA forms a series of lower molecular weight bands. Cells which receive the origin plasmid in the absence of the E1 and E2 expression vectors were completely devoid of any replicated material (see Lanes 5, 6, 12 and 13).
- Hepa1A cells are transfected in four sets. Each set contains 10 ⁇ g of larger ori plasmid pUC/Pst.
- the first set (FIG. 3, Lanes 1-4) contained the 30 ⁇ g of pCMV ⁇ gal in addition to the origin plasmid as control.
- the second set (FIG. 3, Lanes 5-8) contained 15 ⁇ g of pCMV-E1 and pCMV ⁇ gal.
- the third set contained 15 ⁇ g each of pCMV-E2 and pCMV ⁇ gal.
- the final set (FIG. 3, Lanes 9-12) contained 15 ⁇ g each of pCMV-E1 and pCMV-E2.
- the time points for each set are 24, 48, 72 and 96 hours post-transfection.
- Results demonstrate that there is an absolute requirement for E1 and E2 to support episomal BPV-1 replication in hepatoma cells. Similar results were also obtained in two human hepatoma cell lines, HepG2 and PLC. These results demonstrate that the viral origin-containing plasmids replicate episomally in a variety of cell types outside of epithelial and fibroblast lineages. Examples of other cell types which will support episomal vector replication include cells of endothelial, hematopoietic, muscle, nervous and glandular origin.
- Cells are transfected as described previously and whole cell lysates made at various time points post-transfection. Samples are then subjected to RIA analysis with monoclonal antibodies. Bacterially expressed E1 and E2 peptides are used as the standards for this quantitative analysis.
- Confluent cultures of primary hepatocytes are maintained in serum-free media for periods up to one month.
- Primary hepatocyte cultures are used for assessment of plasmid stability and copy number over a longer time frame than possible for proliferating hepatoma cells or C127I cells.
- These cells closely approximate the in vivo condition of the quiescent liver with respect to transcription and replication.
- the rate of transfection of primary hepatocytes with lipofection is approximately 5% to 10%.
- Mouse hepatocytes are plated at a high density (3-4 ⁇ 10 6 cells) in 150 mm dishes in 15 ml of hormonally defined, serum-deficient media. Approximately 20-40 ⁇ g of DNA in 150 ⁇ l of water is mixed with 150 ⁇ g of Lipofection (Gibco/BRL, Gaithersburg, Md.) in 150 ⁇ l water and added to cells for 16 hours in 5% CO 2 incubator maintained at 37° C. Media is aspirated and replaced. Twenty-four hours later cells are trypsinized and replated in multiple 6 cm dishes. At various time points post-transfection cells are harvested and replication assays performed as described in Example 2. In addition, the stability of the input DNA is determined. Long-term maintenance of the targeted DNA even in the absence of episomal replication can be important in achieving long-term expression.
- DNA/Protein complexes allows tissue-specific delivery of the DNA, by utilizing a protein that is recognized by a tissue-specific receptor.
- Hepatocytes contain a unique receptor which recognizes the galactose moiety of asialoglycoproteins (ASGP).
- Orosomucoid (OR) is a highly glycosylated serum protein which upon treatment with neuraminidase yields asialoorosomucoid (ASOR) (M. W. 40,000-60,000), and is cleared rapidly from circulation by the ASGP receptor.
- This liver specific receptor is present at approximately 500,000 receptors per hepatocyte.
- the large number of receptors greatly enhances the delivery capacity of DNA/Protein complexes to hepatocytes in the liver and as a result this type of delivery is very efficient in the expression of desired gene products in the liver.
- the delivery of the episomal vector DNA by DNA/protein complexes to hepatocytes in vivo is used to achieve concentrations of E1 and E2 necessary to support episomal replication in mice.
- the amount of complex, in terms of DNA, injected varies depending upon the amount that gives maximum expression without side effects to the animal.
- rats 200-250 grams
- 0.15M saline, in a volume of 1000 ⁇ l was injected into the tail vein. This resulted in 2-5 ⁇ g of DNA being injected per gram body weight, at a concentration of 0.5-1 ⁇ g/ ⁇ l.
- Various amounts of complex ranging from 0 to 500 ⁇ g (DNA based), in 0.15M saline, are injected at a concentration of 1 ⁇ g/ ⁇ l into the tail vein in two groups of mice (8-10 weeks in age). Control animals are injected with the following at the same DNA concentrations; 1) a mixture of DNA and ASOR, 2) a mixture of DNA and poly-L-lysine, 3) 0.15M saline.
- the analysis of the DNA that has been delivered to the liver and the levels of E1 and E2 produced are measured.
- the replication status of the DNA present is determined with the use of DpnI digestion and Southern blotting.
- Two groups of duplicate C57/B6 mice are injected with the optimum amount of DNA, after which the animals are sacrificed at 0, 12, 24, 48, 72, and 96 hours post-injection.
- the livers are removed and the levels of replicated DNA is determined.
- the intensity of the hybridizing signal is compared to control DNA to estimate how much DNA is present and its half-life in the liver.
- E1 and E2 are measured.
- a set of C57/B6 mice are injected with the maximal amount of DNA. The animals are sacrificed weekly during the first month and then monthly thereafter. The livers are removed, and the levels of the viral proteins are determined by RIA as described in Example 4.
- the episomal vector of the present invention can be used for the treatment of proliferative disease or cancer.
- a therapeutic nucleic acid sequence or sequences is inserted into the episomal vector and a therapeutic dose is introduced into the animal or human to be treated.
- thymidine kinase or another gene whose product results in cell death is delivered to the cancerous cells.
- a variety of delivery methods are available to those skilled in the art to specifically deliver the vector to the proliferative or cancer cells.
- a specific cell line for example a fibroblast or myoblast or hepatocyte or other cell line may be transformed with a papilloma virus episomal vector containing a therapeutic nucleic acid sequence or sequences. Expression of the therapeutic nucleic acid sequence or sequences will result in production of a polypeptide or polypeptides encoded by the therapeutic nucleic acid sequence or sequences.
- the polypeptide(s) may be harvested as is known in the art and utilized to treat a particular disease or condition. Alternatively, the harvested polypeptide(s) may be useful in an affinity chromatography column to bind and isolate a ligand. Additionally, the harvested polypeptide(s) may be used to raise antibodies, such as monoclonal antibodies, in a suitable animal.
- the episomal vector allows for the efficient and versatile production and isolation of a polypeptide for the above recited uses.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
__________________________________________________________________________ SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 3 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3637 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 1: CTGCAGCTGCAATCGTCCATTGCAGAAACATCTGGTTTAGAAAATATTTT50 TGTAGGAGGCTCGGGTTTAGGGGATACAGGAGGAGAAAACATTGAACTGA100 CATACTTCGGGTCCCCACGAACAAGCACGCCCCGCAGTATTGCCTCTAAA150 TCACGTGGCATTTTAAACTGGTTCAGTAAACGGTACTACACACAGGTGCC200 CACGGAAGATCCTGAAGTGTTTTCATCCCAAACATTTGCAAACCCACTGT250 ATGAAGCAGAACCAGCTGTGCTTAAGGGACCTAGTGGACGTGTTGGACTC300 AGTCAGGTTTATAAACCTGATACACTTACAACACGTAGCGGGACAGAGGT350 GGGACCACAGCTACATGTCAGGTACTCATTGAGTACTATACATGAAGATG400 TAGAAGCAATCCCCTACACAGTTGATGAAAATACACAGGGACTTGCATTC450 GTACCCTTGCATGAAGAGCAAGCAGGTTTTGAGGAGATAGAATTAGATGA500 TTTTAGTGAGACACATAGACTGCTACCTCAGAACACCTCTTCTACACCTG550 TTGGTAGTGGTGTACGAAGAAGCCTCATTCCAACTCAGGAATTTAGTGCA600 ACACGGCCTACAGGTGTTGTAACCTATGGCTCACCTGACACTTACTCTGC650 TAGCCCAGTTACTGACCCTGATTCTACCTCTCCTAGTCTAGTTATCGATG700 ACACTACTACTACACCAATCATTATAATTGATGGGCACACAGTTGATTTG750 TACAGCAGTAACTACACCTTGCATCCCTCCTTGTTGAGGAAACGAAAAAA800 ACGGAAACATGCCTAATTTTTTTTGCAGATGGCGTTGTGGCAACAAGGCC850 AGAAGCTGTATCTCCCTCCAACCCCTGTAAGCAAGGTGCTTTGCAGTGAA900 ACCTATGTGCAAAGAAAAAGCATTTTTTATCATGCAGAAACGGAGCGCCT950 GCTAACTATAGGACATCCATATTACCCAGTGTCTATCGGGGCCAAAACTG1000 TTCCTAAGGTCTCTGCAAATCAGTATAGGGTATTTAAAATACAACTACCT1050 GATCCCAATCAATTTGCACTACCTGACAGGACTGTTCACAACCCAAGTAA1100 AGAGCGGCTGGTGTGGGCAGTCATAGGTGTGCAGGTGTCCAGAGGGCAGC1150 CTCTTGGAGGTACTGTAACTGGGCACCCCACTTTTAATGCTTTGCTTGAT1200 GCAGAAAATGTGAATAGAAAAGTCACCACCCAAACAACAGATGACAGGAA1250 ACAAACAGGCCTAGATGCTAAGCAACAACAGATTCTGTTGCTAGGCTGTA1300 CCCCTGCTGAAGGGGAATATTGGACAACAGCCCGTCCATGTGTTACTGAT1350 CGTCTAGAAAATGGCGCCTGCCCTCCTCTTGAATTAAAAAACAAGCACAT1400 AGAAGATGGGGATATGATGGAAATTGGGTTTGGTGCAGCCAACTTCAAAG1450 AAATTAATGCAAGTAAATCAGATCTACCTCTTGACATTCAAAATGAGATC1500 TGCTTGTACCCAGACTACCTCAAAATGGCTGAGGACGCTGCTGGTAATAG1550 CATGTTCTTTTTTGCAAGGAAAGAACAGGTGTATGTTAGACACATCTGGA1600 CCAGAGGGGGCTCGGAGAAAGAAGCCCCTACCACAGATTTTTATTTAAAG1650 AATAATAAAGGGGATGCCACCCTTAAAATACCCAGTGTGCATTTTGGTAG1700 TCCCAGTGGCTCACTAGTCTCAACTGATAATCAAATTTTTAATCGGCCCT1750 ACTGGCTATTCCGTGCCCAGGGCATGAACAATGGAATTGCATGGAATAAT1800 TTATTGTTTTTAACAGTGGGGGACAATACACGTGGTACTAATCTTACCAT1850 AAGTGTAGCCTCAGATGGAACCCCACTAACAGAGTATGATAGCTCAAAAT1900 TCAATGTATACCATAGACATATGGAAGAATATAAGCTAGCCTTTATATTA1950 GAGCTATGCTCTGTGGAAATCACAGCTCAAACTGTGTCACATCTGCAAGG2000 ACTTATGCCCTCTGTGCTTGAAAATTGGGAAATAGGTGTGCAGCCTCCTA2050 CCTCATCGATATTAGAGGACACCTATCGCTATATAGAGTCTCCTGCAACT2100 AAATGTGCAAGCAATGTAATTCCTGCAAAAGAAGACCCTTATGCAGGGTT2150 TAAGTTTTGGAACATAGATCTTAAAGAAAAGCTTTCTTTGGACTTAGATC2200 AATTTCCCTTGGGAAGAAGATTTTTAGCACAGCAAGGGGCAGGATGTTCA2250 ACTGTGAGAAAACGAAGAATTAGCCAAAAAACTTCCAGTAAGCCTGCAAA2300 AAAAAAAAAAAAATAAAAGCTAAGTTTCTATAAATGTTCTGTAAATGTAA2350 AACAGAAGGTAAGTCAACTGCACCTAATAAAAATCACTTAATAGCAATGT2400 GCTGTGTCAGTTGTTTATTGGAACCACACCCGGTACACATCCTGTCCAGC2450 ATTTGCAGTGCGTGCATTGAATTATTGTGCTGGCTAGACTTCATGGCGCC2500 TGGCACCGAATCCTGCCTTCTCAGCGAAAATGAATAATTGCTTTGTTGGC2550 AAGAAACTAAGCATCAATGGGACGCGTGCAAAGCACCGGCGGCGGTAGAT2600 GCGGGGTAAGTACTGAATTTTAATTCGACCTATCCCGGTAAAGCGAAAGC2650 GACACGCTTTTTTTTCACACATAGCGGGACCGAACACGTTATAAGTATCG2700 ATTAGGTCTATTTTTGTCTCTCTGTCGGAACCAGAACTGGTAAAAGTTTC2750 CATTGCGTCTGGGCTTGTCTATCATTGCGTCTCTATGGTTTTTGGAGGAT2800 TAGACGGGGCCACCAGTAATGGTGCATAGCGGATGTCTGTACCGCCATCG2850 GTGCACCGATATAGGTTTGGGGCTCCCCAAGGGACTGCTGGGATGACAGC2900 TTCATATTATATTGAATGGGCGCATAATCAGCTTAATTGGTGAGGACAAG2950 CTACAAGTTGTAACCTGATCTCCACAAAGTACGTTGCCGGTCGGGGTCAA3000 ACCGTCTTCGGTGCTCGAAACCGCCTTAAACTACAGACAGGTCCCAGCCA3050 AGTAGGCGGATCAAAACCTCAAAAAGGCGGGAGCCAATCAAAATGCAGCA3100 TTATATTTTAAGCTCACCGAAACCGGTAAGTAAAGACTATGTATTTTTTC3150 CCAGTGAATAATTGTTGTTAACAATAATCACACCATCACCGTTTTTTCAA3200 GCGGGAAAAAATAGCCAGCTAACTATAAAAAGCTGCTGACAGACCCCGGT3250 TTTCACATGGACCTGAAACCTTTTGCAAGAACCAATCCATTCTCAGGGTT3300 GGATTGTCTGTGGTGCAGAGAGCCTCTTACAGAAGTTGATGCTTTTAGGT3350 GCATGGTCAAAGACTTTCATGTTGTAATTCGGGAAGGCTGTAGATATGGT3400 GCATGTACCATTTGTCTTGAAAACTGTTTAGCTACTGAAAGAAGACTTTG3450 GCAAGGTGTTCCAGTAACAGGTGAGGAAGCTGAATTATTGCATGGCAAAA3500 CACTTGATAGGCTTTGCATAAGATGCTGCTACTGTGGGGGCAAACTAACA3550 AAAAATGAAAAACATCGGCATGTGCTTTTTAATGAGCCTTTCTGCAAAAC3600 CAGAGCTAACATAATTAGAGGACGCTGCTACGACTGC3637 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1451 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 2: ACCTCTTGTGTCCACGTTGTGAATCTCGCGAGCGTCATGGCAAACGATAA50 AGGTAGCAATTGGGATTCGGGCTTGGGATGCTCATATCTGCTGACTGAGG100 CAGAATGTGAAAGTGACAAAGAGAATGAGGAACCCGGGGCAGGTGTAGAA150 CTGTCTGTGGAATCTGATCGGTATGATAGCCAGGATGAGGATTTTGTTGA200 CAATGCATCAGTCTTTCAGGGAAATCACCTGGAGGTCTTCCAGGCATTAG250 AGAAAAAGGCGGGTGAGGAGCAGATTTTAAATTTGAAAAGAAAAGTATTG300 GGGAGTTCGCAAAACAGCAGCGGTTCCGAAGCATCTGAAACTCCAGTTAA350 AAGACGGAAATCAGGAGCAAAGCGAAGATTATTTGCTGAAAANGAAGCTA400 ACCGTGTTCTTACGCCCCTCCAGGTACAGGGGGAGGGGGAGGGGAGGCAA450 GAACTTAATGAGGAGCAGGCAATTAGTCATCTACATCTGCAGCTTGTTAA500 ATCTAAAAATGCTACAGTTTTTAAGCTGGGGCTCTTTAAATCTTTGTTCC550 TTTGTAGCTTCCATGATATTACGAGGTTGTTTAAGAATGATAAGACCACT600 AATCAGCAATGGGTGCTGGCTGTGTTTGGCCTTGCAGAGGTGTTTTTTGA650 GGCGAGTTTCGAACTCCTAAAGAAGCAGTGTAGTTTTCTGCAGATGCAAA700 AAAGATCTCATGAAGGAGGAACTTGTGCAGTTTACTTAATCTGCTTTAAC750 ACAGCTAAAAGCAGAGAAACAGTCCGGAATCTGATGGCAAACACGCTAAA800 TGTAAGAGAAGAGTGTTTGATGCTGCAGCCAGCTAAAATTCGAGGACTCA850 GCGCAGCTCTATTCTGGTTTAAAAGTAGTTTGTCACCCGCTACACTTAAA900 CATGGTGCTTTACCTGAGTGGATACGGGCGCAAACTACTCTGAACGAGAG950 CTTGCAGACCGAGAAATTCGACTTCGGAACTATGGTGCAATGGGCCTATG1000 ATCACAAATATGCTGAGGAGTCTAAAATAGCCTATGAATATGCTTTGGCT1050 GCAGGATCTGATAGCAATGCACGGGCTTTTTTAGCAACTAACAGCCAAGC1100 TAAGCATGTGAAGGACTGTGCAACTATGGTAAGACACTATCTAAGAGCTG1150 AAACACAAGCATTAAGCATGCCTGCATATATTAAAGCTAGGTGCAAGCTG1200 GCAACTGGGGAAGGAAGCTGGAAGTCTATCCTAACTTTTTTTAACTATCA1250 GAATATTGAATTAATTACCTTTATTAATGCTTTAAAGCTCTGGCTAAAAG1300 GAATTCCAAAAAAAAACTGTTTAGCATTTATTGGCCCTCCAAACACAGGC1350 AAGTCTATGCTCTGCAACTCATTAATTCATTTTTTGGGTGGTAGTGTTTT1400 ATCTTTTGCCAACCATAAAAGTCACTTTTGGCTTGCTTCCCTAGCAGATA1450 C1451 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1257 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 3: TTGACGAGGAGGAGGATAGTGAAGAGGATGGAGACAGCATGCGAACGTTT50 ACATGTAGCGCAAGAAACACAAATGCAGTTGATTGAGAAAAGTAGTGATA100 AGTTGCAAGATCATATACTGTACTGGACTGCTGTTAGAACTGAGAACACA150 CTGCTTTATGCTGCAAGGAAAAAAGGGGTGACTGTCCTAGGACACTGCAG200 AGTACCACACTCTGTAGTTTGTCAAGAGAGAGCCAAGCAGGCCATTGAAA250 TGCAGTTGTCTTTGCAGGAGTTAAGCAAAACTGAGTTTGGGGATGAACCA300 TGGTCTTTGCTTGACACAAGCTGGGACCGATATATGTCAGAACCTAAACG350 GTGCTTTAAGAAAGGCGCCAGGGTGGTAGAGGTGGAGTTTGATGGAAATG400 CAAGCAATACAAACTGGTACACTGTCTACAGCAATTTGTACATGCGCACA450 GAGGACGGCTGGCAGCTTGCGAAGGCTGGGGCTGACGGAACTGGGCTCTA500 CTACTGCACCATGGCCGGTGCTGGACGCATTTACTATTCTCGCTTTGGTG550 ACGAGGCAGCCAGATTTAGTACAACAGGGCATTACTCTGTAAGAGATCAG600 GACAGAGTGTATGCTGGTGTCTCATCCACCTCTTCTGATTTTAGAGATCG650 CCCAGACGGAGTCTGGGTCGCATCCGAAGGACCTGAAGGAGACCCTGCAG700 GAAAAGAAGCCGAGCCAGCCCAGCCTGTCTCTTCTTTGCTCGGCTCCCCC750 GCCTGCGGTCCCATCAGAGCAGGCCTCGGTTGGGTACGGGACGGTCCTCG800 CTCGCACCCCTACAATTTTCCTGCAGGCTCGGGGGGCTCTATTCTCCGCT850 CTTCCTCCACCCCGTGCAGGGCACGGTACCGGTGGACTTGGCATCAAGGC900 AGGAAGAAGAGGAGCAGTCGCCCGACTCCACAGAGGAAGAACCAGTGACT950 CTCCCAAGGCGCACCACCAATGATGGATTCCACCTGTTAAAGGCAGGAGG1000 GTCATGCTTTGCTCTAATTTCAGGAACTGCTAACCAGGTAAAGTGCTATC1050 GCTTTCGGGTGAAAAAGAACCATAGACATCGCTACGAGAACTGCACCACC1100 ACCTGGTTCACAGTTGCTGACAACGGTGCTGAAAGACAAGGACAAGCACA1150 AATACTGATCACCTTTGGATCGCCAAGTCAAAGGCAAGACTTTCTGAAAC1200 ATGTACCACTACCTCCTGGAATGAACATTTCCGGCTTTACAGCCAGCTTG1250 GACTTCT1257 __________________________________________________________________________
Claims (39)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/161,286 US5674703A (en) | 1992-12-02 | 1993-12-02 | Episomal vector systems and related methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98440092A | 1992-12-02 | 1992-12-02 | |
US08/161,286 US5674703A (en) | 1992-12-02 | 1993-12-02 | Episomal vector systems and related methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US98440092A Continuation-In-Part | 1992-12-02 | 1992-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
US5674703A true US5674703A (en) | 1997-10-07 |
Family
ID=25530525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/161,286 Expired - Fee Related US5674703A (en) | 1992-12-02 | 1993-12-02 | Episomal vector systems and related methods |
Country Status (3)
Country | Link |
---|---|
US (1) | US5674703A (en) |
AU (1) | AU6014094A (en) |
WO (1) | WO1994012629A1 (en) |
Cited By (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009139A1 (en) * | 1997-08-15 | 1999-02-25 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
WO1999020108A1 (en) * | 1997-10-23 | 1999-04-29 | Uab Research Foundation | Human papillomavirus vectors for the episomal transduction of host cells and method of making same |
WO1999021979A1 (en) * | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
US5929044A (en) * | 1997-08-14 | 1999-07-27 | Cornell Research Foundation | Protein solder composition and method of use |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US6143037A (en) * | 1996-06-12 | 2000-11-07 | The Regents Of The University Of Michigan | Compositions and methods for coating medical devices |
WO2001000203A1 (en) * | 1999-06-25 | 2001-01-04 | Avicena Group, Inc. | Use of creatine or creatine compounds for skin preservation |
WO2001004734A2 (en) * | 1999-07-12 | 2001-01-18 | Sony Computer Entertainment Inc. | Portable information terminal, method of processing audio data, recording medium, and program |
WO2001081384A1 (en) * | 2000-04-27 | 2001-11-01 | Biowindow Gene Development Inc. Shanghai | A novel polypeptide-laminin 16 and the polynucleotide encoding said polypeptide |
WO2001087945A1 (en) * | 2000-04-29 | 2001-11-22 | Shanghai Biowindow Gene Development Inc. | The novel polypeptide-human laminin b2 chain 12 and the polynucliotide encoding said polypeptide |
EP1187841A1 (en) * | 1999-05-28 | 2002-03-20 | Photogen, Inc. | Method for enhanced protein stabilization and production of cell lines useful for production of such stabilized proteins |
US6395253B2 (en) | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
US6413768B1 (en) | 1998-12-02 | 2002-07-02 | University Of Maryland | Expression plasmids |
US6461641B1 (en) * | 1996-07-31 | 2002-10-08 | Fbp Corporation | Tumor delivery vehicles |
US6465246B1 (en) * | 1997-11-21 | 2002-10-15 | Aventis Pharma Deutschland Gmbh | Oncogene- or virus-controlled expression systems |
WO2002082081A2 (en) * | 2001-04-06 | 2002-10-17 | University Of Rochester | Suppression of androgen receptor transactivation through new pathways to ar and ar coactivators and repressors |
US6506378B1 (en) | 1998-12-16 | 2003-01-14 | Arch Development Corporation | Vesicular monoamine transporter gene therapy in Parkinson's disease |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US6605281B1 (en) * | 1998-10-23 | 2003-08-12 | The Uab Research Foundation | Human papillomavirus vectors for the episomal transduction of host cells and method of making same |
US20030170894A1 (en) * | 1996-11-04 | 2003-09-11 | The Regents Of The University Of Michigan | Peptides for gene delivery |
US20030170642A1 (en) * | 2001-03-12 | 2003-09-11 | Irm, Llc | Identification of cellular targets for biologically active molecules |
US20030175819A1 (en) * | 2001-11-28 | 2003-09-18 | Reed John C. | Methods for identifying modulators of apoptosis |
US20030198990A1 (en) * | 1998-07-17 | 2003-10-23 | Chawnshang Chang | Androgen receptor coactivators |
US20030235860A1 (en) * | 1999-11-12 | 2003-12-25 | Chawnshang Chang | Interactions between AR, ER, TR2, and TR4 |
US20040010130A1 (en) * | 2001-02-22 | 2004-01-15 | Motoya Katsuki | Recombinant gene containing inverted repeat sequence and utilization thereof |
US6703233B1 (en) | 1998-12-02 | 2004-03-09 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US6716824B1 (en) | 1999-10-22 | 2004-04-06 | F. Charles Brunicardi | Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy |
US20040076954A1 (en) * | 2001-03-12 | 2004-04-22 | Irm, Llc | Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters |
US6770740B1 (en) | 1999-07-13 | 2004-08-03 | The Regents Of The University Of Michigan | Crosslinked DNA condensate compositions and gene delivery methods |
US6797494B1 (en) * | 1996-08-16 | 2004-09-28 | Medical Research Council | Self-replicating episomal expression vectors conferring tissue-specific gene expression |
US20050003541A1 (en) * | 2001-11-14 | 2005-01-06 | Mitsubishi Chemical Corporation | ES cells having enhanced RNAi effect |
EP1541681A1 (en) * | 2002-07-18 | 2005-06-15 | Mitsubishi Chemical Corporation | METHOD OF CONSTRUCTING NONHUMAN MAMMAL HAVING RNAi PHENOTYPE WITH THE USE OF PAPILOMAVIRUS VECTOR |
US6953579B1 (en) * | 1999-02-11 | 2005-10-11 | Deutches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Chimeric virus-like particle or chimeric capsomers from BPV |
US20050283845A1 (en) * | 2002-12-06 | 2005-12-22 | Mitsubishi Chemical Corporation | Method for producing non-human mammal having RNAi phenotype |
US6995008B1 (en) * | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
USRE39220E1 (en) | 1994-05-11 | 2006-08-01 | Genetic Applications, Llc | Peptide-mediated gene transfer |
US7112434B2 (en) | 2001-05-02 | 2006-09-26 | University Of South Florida | Vector system for selection of genes encoding secreted proteins and membrane-bound proteins |
US20070065432A1 (en) * | 1999-02-22 | 2007-03-22 | Synergene Therapeutics, Inc. | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
US20070071742A1 (en) * | 1998-11-30 | 2007-03-29 | Fang Fang | Humanized antibodies |
US20070248539A1 (en) * | 2006-04-24 | 2007-10-25 | Shantha West Inc. | AgRM2 antigen |
WO2007123579A2 (en) | 2005-12-28 | 2007-11-01 | Translational Therapeutics | Translational dysfunction based therapeutics |
US20070281348A1 (en) * | 1998-12-02 | 2007-12-06 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US20070280879A1 (en) * | 2004-03-11 | 2007-12-06 | Shantha West, Inc. | Therapeutic Use Of Rm1 Antigen |
US20080299121A1 (en) * | 1997-12-01 | 2008-12-04 | Fang Fang | Multivalent recombinant antibodies for treating HRV infections |
US20090011996A1 (en) * | 2007-07-06 | 2009-01-08 | University Of Louisville Research Foundation, Inc. | Diagnosing and protecting horses against papillomavirus |
US20090074730A1 (en) * | 2005-11-22 | 2009-03-19 | Ottawa Health Research Institute | Novel stem cells, nucleotide sequences and proteins therefrom |
US20090105196A1 (en) * | 2007-06-22 | 2009-04-23 | Belinda Tsao Nivaggioli | Use of creatine compounds to treat dermatitis |
US20100143408A1 (en) * | 2007-01-30 | 2010-06-10 | Martine Baudin | Papillomavirus vaccines |
WO2010117057A1 (en) | 2009-04-10 | 2010-10-14 | 協和発酵キリン株式会社 | Method for treatment of blood tumor using anti-tim-3 antibody |
WO2010126066A1 (en) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | Anti-il-3rα antibody for use in treatment of blood tumor |
US20110020374A1 (en) * | 2007-10-15 | 2011-01-27 | The University Of Queensland | Expression system for modulating an immune response |
EP2295465A2 (en) | 2004-12-06 | 2011-03-16 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
EP2298357A1 (en) | 2000-03-13 | 2011-03-23 | Engene, Inc. | Compositions and methods for regulated protein expression in gut |
US20110126303A1 (en) * | 2000-03-22 | 2011-05-26 | The Children's Hospital Of Philadelphia | Modified Blood Clotting Factors And Methods Of Use |
EP2431053A1 (en) | 2006-11-27 | 2012-03-21 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
US8211487B2 (en) | 2008-11-26 | 2012-07-03 | Srinivasan Damodaran | Inhibition of ice crystal growth |
EP2537522A1 (en) | 2007-08-02 | 2012-12-26 | California Stem Cell, Inc. | Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells |
US8394771B1 (en) | 2001-07-19 | 2013-03-12 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
WO2013070529A1 (en) | 2011-11-09 | 2013-05-16 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the interaction between cftr and cal |
US20140107036A1 (en) * | 2011-04-26 | 2014-04-17 | M. Peter Marinkovich | Production and Delivery of a Stable Collagen |
WO2014070957A1 (en) | 2012-10-30 | 2014-05-08 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
WO2014105939A1 (en) | 2012-12-27 | 2014-07-03 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
WO2014210142A1 (en) | 2013-06-25 | 2014-12-31 | Temple University-Of The Commonwealth System Of Higher Education | Cortical bone-derived stem cells |
US20150343047A1 (en) * | 1994-11-08 | 2015-12-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical dysplasia |
WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
EP3098238A1 (en) | 2005-11-25 | 2016-11-30 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
WO2016200997A1 (en) * | 2015-06-10 | 2016-12-15 | America Gene Technologies International, Inc. | Non-integrating viral delivery system and methods of use thereof |
US9556272B2 (en) | 2009-11-11 | 2017-01-31 | The Trustees Of The University Of Pennsylvania | Anti-TEM1 antibodies and uses thereof |
WO2017069291A1 (en) | 2015-10-23 | 2017-04-27 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
WO2017096432A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
US9790269B2 (en) | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
US9834790B1 (en) | 2016-01-15 | 2017-12-05 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US9901639B2 (en) | 2015-02-13 | 2018-02-27 | Temple University—Of the Commonwealth System of Higher Education | Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease |
US10036038B2 (en) | 2016-07-08 | 2018-07-31 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
WO2018232079A1 (en) | 2017-06-14 | 2018-12-20 | Daley George Q | Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer |
US10548914B2 (en) | 2008-10-17 | 2020-02-04 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
US10767183B2 (en) | 2016-03-09 | 2020-09-08 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
WO2022147463A2 (en) | 2020-12-31 | 2022-07-07 | Alamar Biosciences, Inc. | Binder molecules with high affinity and/ or specificity and methods of making and use thereof |
US11583562B2 (en) | 2016-07-21 | 2023-02-21 | American Gene Technologies International Inc. | Viral vectors for treating Parkinson's disease |
US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
EP4306165A2 (en) | 2011-07-01 | 2024-01-17 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
US11976292B2 (en) | 2016-06-08 | 2024-05-07 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11507352A (en) | 1995-06-07 | 1999-06-29 | ジンタ・インコーポレイテッド | New carbamate-based cationic lipids |
AUPN443995A0 (en) | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
US5801030A (en) * | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
US6479279B2 (en) | 1995-12-29 | 2002-11-12 | Estonian Biocentre | Episomal vectors and uses thereof |
CA2241172C (en) * | 1995-12-29 | 2008-08-19 | Estonian Biocentre | Episomal vector and uses thereof |
US6689757B1 (en) | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
DE19635568C1 (en) * | 1996-09-02 | 1998-03-26 | Gsf Forschungszentrum Umwelt | Vector systems for conditional gene expression |
IL129103A0 (en) | 1996-10-01 | 2000-02-17 | Geron Corp | Human telomerase catalytic subunit and pharmaceutical compositions containing same |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
FI107737B (en) * | 1999-12-23 | 2001-09-28 | Atso Raasmaja | Plasmid for expression of the tyrosine hydroxylase gene in the brain |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
FI116851B (en) | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Expression vector, its uses and process for its preparation and products containing it |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
EA013752B1 (en) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8357781B2 (en) | 2006-06-01 | 2013-01-22 | Janssen Alzheimer Immunotherapy | Neuroactive fragments of APP |
EP1900749A1 (en) | 2006-09-12 | 2008-03-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells |
ES2570182T3 (en) | 2007-02-23 | 2016-05-17 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2118300B1 (en) | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CA2697992C (en) | 2007-10-04 | 2017-08-22 | Zymogenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
US8779088B2 (en) | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
SG186689A1 (en) | 2007-12-28 | 2013-01-30 | Univ Tennessee Res Foundation | Treatment and prophylaxis of amyloidosis |
RU2010151562A (en) | 2008-06-20 | 2012-07-27 | ВАЙЕТ ЭлЭлСи (US) | COMPOSITIONS AND METHODS OF APPLICATION OF ORF1358 FROM BETA-HEMOLYTIC STRAPTOCOK STRAINS |
AU2010234849B2 (en) | 2009-03-30 | 2017-06-22 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
CA2792537A1 (en) | 2010-03-30 | 2011-10-06 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
EP2580238A1 (en) | 2010-06-09 | 2013-04-17 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
US9518101B2 (en) | 2011-09-19 | 2016-12-13 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
EP4241785A3 (en) | 2011-09-20 | 2023-09-27 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
MX2015007755A (en) | 2012-12-18 | 2016-01-14 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof. |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
JP2018504412A (en) | 2015-01-23 | 2018-02-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | Influenza virus vaccination regimen |
CU24537B1 (en) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 3D6 ANTIBODY |
HUE060258T2 (en) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunotherapy |
EP3452509A1 (en) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
CA3023143A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
MX2019013045A (en) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Antibodies recognizing tau. |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
TW202128775A (en) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | Pd-l1 inhibitor - tgfβ inhibitor bispecific drug moieties |
BR112022023366A2 (en) | 2020-05-19 | 2023-05-02 | Othair Prothena Ltd | MULTIPLE EPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER DISEASE |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
-
1993
- 1993-12-02 AU AU60140/94A patent/AU6014094A/en not_active Abandoned
- 1993-12-02 US US08/161,286 patent/US5674703A/en not_active Expired - Fee Related
- 1993-12-02 WO PCT/US1993/011666 patent/WO1994012629A1/en active Application Filing
Non-Patent Citations (20)
Title |
---|
Baker and Howley, "Differential Promoter Utilization by the Bovine Papillomavirus in Transformed Cells and Productively Infected Wart Tissues", 6(4) EMBO J. 1027, 1987. |
Baker and Howley, Differential Promoter Utilization by the Bovine Papillomavirus in Transformed Cells and Productively Infected Wart Tissues , 6(4) EMBO J. 1027, 1987. * |
Chen et al., "The Primary Structure and Genetic Organization of the bovine Papillomavirus Type 1 Genome", 299 Nature 529, 1987. |
Chen et al., The Primary Structure and Genetic Organization of the bovine Papillomavirus Type 1 Genome , 299 Nature 529, 1987. * |
Culver et al., "In vivo Gene Transfer with Retroviral Vectro-Producer Cells for Treatment of Experimental Brain Tumors", 256 Science 1550, 1992. |
Culver et al., In vivo Gene Transfer with Retroviral Vectro Producer Cells for Treatment of Experimental Brain Tumors , 256 Science 1550, 1992. * |
Ledley, "Somatic Gene Therapy for Human Disease: Background and Prospects. Part 1", 110(1) J. Pediatrics 1, 1987. |
Ledley, Somatic Gene Therapy for Human Disease: Background and Prospects. Part 1 , 110(1) J. Pediatrics 1, 1987. * |
Lusky et al., "A Bovine Papilloma Virus Type 1--Encoded Modulator Function is Dispensable for Transient Viral Replication But is Required for Establishment of the Stable Plasmid Site", 60(2) J. Virology 729, 1986. |
Lusky et al., "Characterization of the Bovine Papilloma Virus Plasmid Maintenance Sequences", 36(2) Cell 391, 1984. |
Lusky et al., A Bovine Papilloma Virus Type 1 Encoded Modulator Function is Dispensable for Transient Viral Replication But is Required for Establishment of the Stable Plasmid Site , 60(2) J. Virology 729, 1986. * |
Lusky et al., Characterization of the Bovine Papilloma Virus Plasmid Maintenance Sequences , 36(2) Cell 391, 1984. * |
Sarver et al., "Bovine Papilloma Virus Deoxyribonucleic Acid: A Novel Eucaryotic Cloning Vectro", 1(6) Molec. Cell Biol. 486, 1981. |
Sarver et al., Bovine Papilloma Virus Deoxyribonucleic Acid: A Novel Eucaryotic Cloning Vectro , 1(6) Molec. Cell Biol. 486, 1981. * |
Spalholz et al., "Transactivation of a Bovine Papilloma Virus Transcriptional Regulatory Element by the E2 Gene Product", 42 Cell 183, 1985. |
Spalholz et al., Transactivation of a Bovine Papilloma Virus Transcriptional Regulatory Element by the E2 Gene Product , 42 Cell 183, 1985. * |
Ustav and Stenlund, "Transient Replication of BPV-1 Requires Two viral Polypeptides Encoded by the E1 and E2 Open Reading Frames", 10(2) EMBO J. 449, 1991. |
Ustav and Stenlund, Transient Replication of BPV 1 Requires Two viral Polypeptides Encoded by the E1 and E2 Open Reading Frames , 10(2) EMBO J. 449, 1991. * |
Ustav et al., "Identification of the Origin of Replication of Bovine Papillomavirus and characterization of the Viral Orgin Recognition Factor E1", 10 (13) EMBO J. 4321, 1991. |
Ustav et al., Identification of the Origin of Replication of Bovine Papillomavirus and characterization of the Viral Orgin Recognition Factor E1 , 10 (13) EMBO J. 4321, 1991. * |
Cited By (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US6995008B1 (en) * | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
USRE39220E1 (en) | 1994-05-11 | 2006-08-01 | Genetic Applications, Llc | Peptide-mediated gene transfer |
US20150343047A1 (en) * | 1994-11-08 | 2015-12-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical dysplasia |
US6143037A (en) * | 1996-06-12 | 2000-11-07 | The Regents Of The University Of Michigan | Compositions and methods for coating medical devices |
US6461641B1 (en) * | 1996-07-31 | 2002-10-08 | Fbp Corporation | Tumor delivery vehicles |
US6797494B1 (en) * | 1996-08-16 | 2004-09-28 | Medical Research Council | Self-replicating episomal expression vectors conferring tissue-specific gene expression |
US7112442B2 (en) | 1996-11-04 | 2006-09-26 | The Regents Of The University Of Michigan | Peptides for gene delivery |
US20030170894A1 (en) * | 1996-11-04 | 2003-09-11 | The Regents Of The University Of Michigan | Peptides for gene delivery |
US5929044A (en) * | 1997-08-14 | 1999-07-27 | Cornell Research Foundation | Protein solder composition and method of use |
WO1999009139A1 (en) * | 1997-08-15 | 1999-02-25 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
WO1999020108A1 (en) * | 1997-10-23 | 1999-04-29 | Uab Research Foundation | Human papillomavirus vectors for the episomal transduction of host cells and method of making same |
WO1999021979A1 (en) * | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
US6399383B1 (en) * | 1997-10-28 | 2002-06-04 | Maxygen, Inc. | Human papilloma virus vectors |
US6465246B1 (en) * | 1997-11-21 | 2002-10-15 | Aventis Pharma Deutschland Gmbh | Oncogene- or virus-controlled expression systems |
US20080299121A1 (en) * | 1997-12-01 | 2008-12-04 | Fang Fang | Multivalent recombinant antibodies for treating HRV infections |
US6395253B2 (en) | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
US20050164179A9 (en) * | 1998-07-17 | 2005-07-28 | Chawnshang Chang | Androgen receptor coactivators |
US7052908B2 (en) | 1998-07-17 | 2006-05-30 | University Of Rochester | Androgen receptor coactivators |
US6699714B1 (en) | 1998-07-17 | 2004-03-02 | University Of Rochester | Androgen receptor coactivators |
US20030198990A1 (en) * | 1998-07-17 | 2003-10-23 | Chawnshang Chang | Androgen receptor coactivators |
US6605281B1 (en) * | 1998-10-23 | 2003-08-12 | The Uab Research Foundation | Human papillomavirus vectors for the episomal transduction of host cells and method of making same |
US8586712B2 (en) | 1998-11-30 | 2013-11-19 | Perlan Therapeutics, Inc. | Humanized antibodies |
US7696324B2 (en) | 1998-11-30 | 2010-04-13 | Perlan Therapeutics, Inc. | Humanized antibodies |
US20070071742A1 (en) * | 1998-11-30 | 2007-03-29 | Fang Fang | Humanized antibodies |
US20110044976A1 (en) * | 1998-11-30 | 2011-02-24 | Perlan Therapeutics | Humanized antibodies |
US6703233B1 (en) | 1998-12-02 | 2004-03-09 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US6977176B2 (en) | 1998-12-02 | 2005-12-20 | University Of Maryland | Plasmid maintenance system for antigen delivery |
US8076130B2 (en) | 1998-12-02 | 2011-12-13 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US7125720B2 (en) | 1998-12-02 | 2006-10-24 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US20060030047A1 (en) * | 1998-12-02 | 2006-02-09 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US20060030048A1 (en) * | 1998-12-02 | 2006-02-09 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US20060029616A1 (en) * | 1998-12-02 | 2006-02-09 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US20040161420A1 (en) * | 1998-12-02 | 2004-08-19 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US6413768B1 (en) | 1998-12-02 | 2002-07-02 | University Of Maryland | Expression plasmids |
US20070281348A1 (en) * | 1998-12-02 | 2007-12-06 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US7138112B2 (en) | 1998-12-02 | 2006-11-21 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US6969513B2 (en) | 1998-12-02 | 2005-11-29 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US7141408B2 (en) | 1998-12-02 | 2006-11-28 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
US7115258B2 (en) | 1998-12-16 | 2006-10-03 | Arch Development Corp. | Vesicular monoamine transporter gene therapy in parkinson's disease |
US20090036393A1 (en) * | 1998-12-16 | 2009-02-05 | The University Of Chicago | Vesicular monoamine transporter gene therapy in Parkinson's disease |
US6506378B1 (en) | 1998-12-16 | 2003-01-14 | Arch Development Corporation | Vesicular monoamine transporter gene therapy in Parkinson's disease |
US6953579B1 (en) * | 1999-02-11 | 2005-10-11 | Deutches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Chimeric virus-like particle or chimeric capsomers from BPV |
US20090191261A1 (en) * | 1999-02-22 | 2009-07-30 | Synergene Therapeutics, Inc. | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
US8859274B2 (en) | 1999-02-22 | 2014-10-14 | Synergene Therapeutics, Inc. | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
US20070065432A1 (en) * | 1999-02-22 | 2007-03-22 | Synergene Therapeutics, Inc. | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
EP1187841A4 (en) * | 1999-05-28 | 2004-12-08 | Photogen Inc | Method for enhanced protein stabilization and production of cell lines useful for production of such stabilized proteins |
EP1187841A1 (en) * | 1999-05-28 | 2002-03-20 | Photogen, Inc. | Method for enhanced protein stabilization and production of cell lines useful for production of such stabilized proteins |
US20050186195A1 (en) * | 1999-06-25 | 2005-08-25 | Avicena Group, Inc | Use of creatine or creatine compounds for skin preservation |
US20050227996A1 (en) * | 1999-06-25 | 2005-10-13 | Avicena Group, Inc. | Use of creatine or creatine compounds for skin preservation |
US7186754B2 (en) | 1999-06-25 | 2007-03-06 | Avicena Group, Inc. | Use of creatine or creatine compounds for skin preservation |
US20050186194A1 (en) * | 1999-06-25 | 2005-08-25 | Avicena Group, Inc. | Use of creatine or creatine compounds for skin preservation |
EP2397127A1 (en) * | 1999-06-25 | 2011-12-21 | Enerdermics, Inc. | Use of creatine or creatine compounds for skin preservation |
WO2001000203A1 (en) * | 1999-06-25 | 2001-01-04 | Avicena Group, Inc. | Use of creatine or creatine compounds for skin preservation |
US6242491B1 (en) | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
WO2001004734A3 (en) * | 1999-07-12 | 2001-03-29 | Sony Computer Entertainment Inc | Portable information terminal, method of processing audio data, recording medium, and program |
WO2001004734A2 (en) * | 1999-07-12 | 2001-01-18 | Sony Computer Entertainment Inc. | Portable information terminal, method of processing audio data, recording medium, and program |
US6770740B1 (en) | 1999-07-13 | 2004-08-03 | The Regents Of The University Of Michigan | Crosslinked DNA condensate compositions and gene delivery methods |
US20050137157A1 (en) * | 1999-10-22 | 2005-06-23 | Charles F. Brunicardi, M.D. | Treating hyperinsulinemia by killing beta cells with cytotoxic gene |
US6716824B1 (en) | 1999-10-22 | 2004-04-06 | F. Charles Brunicardi | Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy |
US20050059620A1 (en) * | 1999-10-22 | 2005-03-17 | F. Charles Brunicardi | Promoter driven tissue specific cytotoxic agents and title methods of use |
US20030235860A1 (en) * | 1999-11-12 | 2003-12-25 | Chawnshang Chang | Interactions between AR, ER, TR2, and TR4 |
EP2298357A1 (en) | 2000-03-13 | 2011-03-23 | Engene, Inc. | Compositions and methods for regulated protein expression in gut |
US20110126303A1 (en) * | 2000-03-22 | 2011-05-26 | The Children's Hospital Of Philadelphia | Modified Blood Clotting Factors And Methods Of Use |
WO2001081384A1 (en) * | 2000-04-27 | 2001-11-01 | Biowindow Gene Development Inc. Shanghai | A novel polypeptide-laminin 16 and the polynucleotide encoding said polypeptide |
WO2001087945A1 (en) * | 2000-04-29 | 2001-11-22 | Shanghai Biowindow Gene Development Inc. | The novel polypeptide-human laminin b2 chain 12 and the polynucliotide encoding said polypeptide |
US20040010130A1 (en) * | 2001-02-22 | 2004-01-15 | Motoya Katsuki | Recombinant gene containing inverted repeat sequence and utilization thereof |
US20040076954A1 (en) * | 2001-03-12 | 2004-04-22 | Irm, Llc | Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters |
US20030170642A1 (en) * | 2001-03-12 | 2003-09-11 | Irm, Llc | Identification of cellular targets for biologically active molecules |
US20040235717A1 (en) * | 2001-04-06 | 2004-11-25 | Chawnshang Chang | Suppression of androgen receptor transactivation through new pathways to ar and ar coactivators and repressors |
WO2002082081A3 (en) * | 2001-04-06 | 2003-01-16 | Univ Rochester | Suppression of androgen receptor transactivation through new pathways to ar and ar coactivators and repressors |
WO2002082081A2 (en) * | 2001-04-06 | 2002-10-17 | University Of Rochester | Suppression of androgen receptor transactivation through new pathways to ar and ar coactivators and repressors |
US7112434B2 (en) | 2001-05-02 | 2006-09-26 | University Of South Florida | Vector system for selection of genes encoding secreted proteins and membrane-bound proteins |
US20070111283A1 (en) * | 2001-05-02 | 2007-05-17 | Cannon John P | Vector system for selection of genes encoding secreted proteins and membrane-bound proteins |
US8394771B1 (en) | 2001-07-19 | 2013-03-12 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
EP2336186A1 (en) | 2001-07-19 | 2011-06-22 | Perlan Therapeutics, Inc. | Humanized antibodies against ICAM-1, their production and uses |
US20050003541A1 (en) * | 2001-11-14 | 2005-01-06 | Mitsubishi Chemical Corporation | ES cells having enhanced RNAi effect |
US20070033663A1 (en) * | 2001-11-14 | 2007-02-08 | Mitsubishi Chemical Corporation | ES cells having enhanced RNAi effect |
US20090075292A1 (en) * | 2001-11-28 | 2009-03-19 | The Burnham Institute | Methods for identifying modulators of apoptosis |
US7422862B2 (en) | 2001-11-28 | 2008-09-09 | The Burnham Institute | Methods for identifying modulators of apoptosis |
US20110230364A1 (en) * | 2001-11-28 | 2011-09-22 | Sanford-Burnham Medical Research Institute | Methods for identifying modulators of apoptosis |
US7927816B2 (en) | 2001-11-28 | 2011-04-19 | Sanford-Burnham Medical Research Institute | Methods for identifying modulators of apoptosis |
US20030175819A1 (en) * | 2001-11-28 | 2003-09-18 | Reed John C. | Methods for identifying modulators of apoptosis |
EP1541681A1 (en) * | 2002-07-18 | 2005-06-15 | Mitsubishi Chemical Corporation | METHOD OF CONSTRUCTING NONHUMAN MAMMAL HAVING RNAi PHENOTYPE WITH THE USE OF PAPILOMAVIRUS VECTOR |
US20050229266A1 (en) * | 2002-07-18 | 2005-10-13 | Mitsubishi Chemical Corporation | Method for producing non-human mammal RNAi phenotype using papilloma virus vector |
EP1541681A4 (en) * | 2002-07-18 | 2006-05-17 | Mitsubishi Chem Corp | METHOD OF CONSTRUCTING NONHUMAN MAMMAL HAVING RNAi PHENOTYPE WITH THE USE OF PAPILOMAVIRUS VECTOR |
US20050283845A1 (en) * | 2002-12-06 | 2005-12-22 | Mitsubishi Chemical Corporation | Method for producing non-human mammal having RNAi phenotype |
US20070280879A1 (en) * | 2004-03-11 | 2007-12-06 | Shantha West, Inc. | Therapeutic Use Of Rm1 Antigen |
EP2295465A2 (en) | 2004-12-06 | 2011-03-16 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
US8101407B2 (en) | 2005-11-22 | 2012-01-24 | Ottawa Health Research Institute | Stem cells, nucleotide sequences and proteins therefrom |
US8679833B2 (en) | 2005-11-22 | 2014-03-25 | Ottawa Health Research Institute | Stem cells, nucleotide sequences and proteins therefrom |
US20090074730A1 (en) * | 2005-11-22 | 2009-03-19 | Ottawa Health Research Institute | Novel stem cells, nucleotide sequences and proteins therefrom |
EP3098238A1 (en) | 2005-11-25 | 2016-11-30 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
EP3345927A1 (en) | 2005-11-25 | 2018-07-11 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
EP4219557A1 (en) | 2005-11-25 | 2023-08-02 | Kyowa Kirin Co., Ltd. | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
WO2007123579A2 (en) | 2005-12-28 | 2007-11-01 | Translational Therapeutics | Translational dysfunction based therapeutics |
US20070248539A1 (en) * | 2006-04-24 | 2007-10-25 | Shantha West Inc. | AgRM2 antigen |
EP2431053A1 (en) | 2006-11-27 | 2012-03-21 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
US8420103B2 (en) * | 2007-01-30 | 2013-04-16 | Transgene S.A. | Papillomavirus vaccines |
US20100143408A1 (en) * | 2007-01-30 | 2010-06-10 | Martine Baudin | Papillomavirus vaccines |
US20090105196A1 (en) * | 2007-06-22 | 2009-04-23 | Belinda Tsao Nivaggioli | Use of creatine compounds to treat dermatitis |
US20090011996A1 (en) * | 2007-07-06 | 2009-01-08 | University Of Louisville Research Foundation, Inc. | Diagnosing and protecting horses against papillomavirus |
WO2009009430A1 (en) * | 2007-07-06 | 2009-01-15 | University Of Louisville Research Foundation, Inc. | Diagnosing and protecting horses against papillomavirus |
US20100317567A1 (en) * | 2007-07-06 | 2010-12-16 | University Of Louisville Research Foundation, Inc. | Diagnosing and protecting horses against papillomavirus |
EP2537522A1 (en) | 2007-08-02 | 2012-12-26 | California Stem Cell, Inc. | Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells |
US9593340B2 (en) | 2007-10-15 | 2017-03-14 | Admedus Vaccines Pty Ltd. | Expression system for modulating an immune response |
US20110020374A1 (en) * | 2007-10-15 | 2011-01-27 | The University Of Queensland | Expression system for modulating an immune response |
US11617760B2 (en) | 2008-10-17 | 2023-04-04 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
US11007209B2 (en) | 2008-10-17 | 2021-05-18 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
US10548914B2 (en) | 2008-10-17 | 2020-02-04 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
US8211487B2 (en) | 2008-11-26 | 2012-07-03 | Srinivasan Damodaran | Inhibition of ice crystal growth |
WO2010117057A1 (en) | 2009-04-10 | 2010-10-14 | 協和発酵キリン株式会社 | Method for treatment of blood tumor using anti-tim-3 antibody |
EP2949673A1 (en) | 2009-04-27 | 2015-12-02 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
WO2010126066A1 (en) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | Anti-il-3rα antibody for use in treatment of blood tumor |
US9556272B2 (en) | 2009-11-11 | 2017-01-31 | The Trustees Of The University Of Pennsylvania | Anti-TEM1 antibodies and uses thereof |
US11078285B2 (en) | 2009-11-11 | 2021-08-03 | The Trustees Of The University Of Pennsylvania | Anti-TEM1 antibodies and uses thereof |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
US9040484B2 (en) * | 2011-04-26 | 2015-05-26 | The Board Of Trustees Of The Leland Stanford Junior University | Production and delivery of a stable collagen |
US9403895B2 (en) | 2011-04-26 | 2016-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Production and delivery of a stable collagen |
US20140107036A1 (en) * | 2011-04-26 | 2014-04-17 | M. Peter Marinkovich | Production and Delivery of a Stable Collagen |
EP4306165A2 (en) | 2011-07-01 | 2024-01-17 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
WO2013070529A1 (en) | 2011-11-09 | 2013-05-16 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the interaction between cftr and cal |
US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
WO2014070957A1 (en) | 2012-10-30 | 2014-05-08 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
EP4035685A1 (en) | 2012-10-30 | 2022-08-03 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
WO2014105939A1 (en) | 2012-12-27 | 2014-07-03 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
EP4083221A1 (en) | 2012-12-27 | 2022-11-02 | NGM Biopharmaceuticals, Inc. | Chimeric fgf19 peptides for use in treating bile acid disorders |
US9790269B2 (en) | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
WO2014210142A1 (en) | 2013-06-25 | 2014-12-31 | Temple University-Of The Commonwealth System Of Higher Education | Cortical bone-derived stem cells |
WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
US9901639B2 (en) | 2015-02-13 | 2018-02-27 | Temple University—Of the Commonwealth System of Higher Education | Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease |
WO2016200997A1 (en) * | 2015-06-10 | 2016-12-15 | America Gene Technologies International, Inc. | Non-integrating viral delivery system and methods of use thereof |
US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
WO2017069291A1 (en) | 2015-10-23 | 2017-04-27 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
EP3888672A1 (en) | 2015-11-09 | 2021-10-06 | NGM Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
WO2017096432A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
US10023880B2 (en) | 2016-01-15 | 2018-07-17 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US9914938B2 (en) | 2016-01-15 | 2018-03-13 | American Gene Technologies International, Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US10772905B2 (en) | 2016-01-15 | 2020-09-15 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US11519006B2 (en) | 2016-01-15 | 2022-12-06 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US10472649B2 (en) | 2016-01-15 | 2019-11-12 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US10036040B2 (en) | 2016-01-15 | 2018-07-31 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US10428350B2 (en) | 2016-01-15 | 2019-10-01 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US10420789B2 (en) | 2016-01-15 | 2019-09-24 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US9834790B1 (en) | 2016-01-15 | 2017-12-05 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
US10975374B2 (en) | 2016-03-09 | 2021-04-13 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
US10767183B2 (en) | 2016-03-09 | 2020-09-08 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
US11976292B2 (en) | 2016-06-08 | 2024-05-07 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
US10036038B2 (en) | 2016-07-08 | 2018-07-31 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
US10494647B2 (en) | 2016-07-08 | 2019-12-03 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
US11911458B2 (en) | 2016-07-08 | 2024-02-27 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
US10233464B2 (en) | 2016-07-08 | 2019-03-19 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
US11090379B2 (en) | 2016-07-08 | 2021-08-17 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
US11583562B2 (en) | 2016-07-21 | 2023-02-21 | American Gene Technologies International Inc. | Viral vectors for treating Parkinson's disease |
US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
WO2018232079A1 (en) | 2017-06-14 | 2018-12-20 | Daley George Q | Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer |
WO2022147463A2 (en) | 2020-12-31 | 2022-07-07 | Alamar Biosciences, Inc. | Binder molecules with high affinity and/ or specificity and methods of making and use thereof |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Also Published As
Publication number | Publication date |
---|---|
WO1994012629A1 (en) | 1994-06-09 |
AU6014094A (en) | 1994-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5674703A (en) | Episomal vector systems and related methods | |
WO1994012629A9 (en) | Episomal vectors for gene therapy | |
Wu et al. | Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo | |
Yang | Gene transfer into mammalian somatic cells in vivo | |
Ferkol et al. | Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor. | |
US5656610A (en) | Producing a protein in a mammal by injection of a DNA-sequence into the tongue | |
EP0918874B1 (en) | Self-replicating episomal expression vectors conferring tissue-specific gene expression | |
Jiao et al. | Particle bombardment-mediated gene transfer and expression in rat brain tissues | |
EP1104309B1 (en) | Co-lyophilized complex comprising a nucleic acid vector and a formulating agent | |
US6103226A (en) | Genetically engineered cells that produce produce L. Dopa | |
WO2001090345A2 (en) | Methods and compositions for enhancing the delivery of a nucleic acid to a cell | |
US6040172A (en) | Defective DNA viral vector comprising a neural tissue-specific promoter for in vivo expression of a gene | |
CA2139948C (en) | Targeting somatic gene therapy to joints | |
CA2308575A1 (en) | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof | |
US7364750B2 (en) | Autogene nucleic acids encoding a secretable RNA polymerase | |
US6225082B1 (en) | Myelin basic protein MRNA transport and translation enhancer sequences | |
US6709858B1 (en) | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof | |
AU712208B2 (en) | Glucocorticoid enhancement of gene expression | |
Mizuguchi et al. | Cytoplasmic Gene Expression System Enhances the Efficiency of Cationic Liposome-Mediatedin VivoGene Transfer into Mouse Brain | |
JP3808938B2 (en) | Nucleic acid carrier | |
US6797494B1 (en) | Self-replicating episomal expression vectors conferring tissue-specific gene expression | |
KR20020013476A (en) | Novel system for regulating transgene expression | |
CA2250759A1 (en) | A cytoplasmic gene expression system which utilizes a prokaryotic rna polymerase autogene | |
US20080194540A1 (en) | Use of a Tricyclic Antidepressant Drug For Promoting Endocytosis | |
Oh et al. | Lactoferrin as a gene delivery vehicle to hepatocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COLD SPRING HARBOR LABORATORY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STENLUND, ARNE;REEL/FRAME:008610/0722 Effective date: 19970602 Owner name: BAYLOR COLLEGE OF MEDICINE, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NORDLOH, PETER W.;WOO, SAVIO L.C.;REEL/FRAME:008610/0729;SIGNING DATES FROM 19970327 TO 19970509 |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20051007 |